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Photoacoustic (PA) imaging is an emerging biomedical imaging modality that combines 
optical and ultrasound imaging technologies. PA imaging relies on the absorption of 
electromagnetic energy (usually in the form of visible or near-infrared light) leading to the 
generation of acoustic waves by thermoelastic expansion, which can be detected with an 
ultrasound detector. PA imaging can be used to detect endogenous chromophores such 
as deoxyhemoglobin and oxyhemoglobin, or can be used together with external 
nanosensors for added functionality. The former is used to measure things like blood 
oxygenation, while the latter opens up many possibilities for PA imaging, limited only to 
the availability of optical nanosensors. In this dissertation, I employ the use of PA 
nanosensors for contrast enhancement and molecular imaging in in vivo small animal 
cancer models. 
In the first section, I introduce a novel PA background reduction technique called the 
transient triplet differential (TTD) method. The TTD method exploits the fact that 
phosphorescent dyes possess a triplet state with a unique red-shifted absorption 
wavelength, distinct from its ordinary singlet state absorption profile. By pumping these 
dyes into the triplet state and comparing the signal to the unpumped dyes, a differential 
signal can be obtained which solely originates from these dyes. Since intrinsic 




the triplet state, the TTD method can facilitate “true” background free molecular imaging 
by excluding the signals from every other chromophore outside the phosphorescent dye. 
Here, I demonstrate up to an order of magnitude better sensitivity of the TTD method 
compared to other existing contrast enhancement techniques in both in vitro experiments 
and in vivo cancer models.  
In the second section, I explore the use of a nanoparticle formulation of a repurposed 
FDA-approved drug called clofazimine for diagnosis of prostate cancer. Clofazimine 
nanoparticles have a high optical absorbance at 495 nm and has been known to 
specifically accumulate in macrophages as they form stable crystal-like inclusions once 
they are uptaken by macrophages. Due to the presence of tumor associated 
macrophages, it is expected that clofazimine would accumulate in much higher quantities 
in the cancerous prostate compared to normal prostates. Here, I show that there was 
indeed a significantly higher accumulation of clofazimine nanoparticles in cancerous 
prostates compared to normal prostates in a transgenic mouse model, which was 
detectable both using histology and ex vivo PA imaging. 
In the third and final section, I explore the use of a potassium (K+) nanosensor together 
with PA imaging in measuring the in vivo K+ distribution in the tumor microenvironment 
(TME). K+ is the most abundant ion in the body and has recently been shown to be at a 
significantly higher concentration in the tumor. The reported 5-10 fold elevation (25-50 
mM compared to 5mM) in the tumor has been shown to inhibit immune cell efficacy, and 
thus immunotherapy. Despite the abundance and importance of K+ in the body, few ways 
exist to measure it in vivo. In this study, a solvatochromic dye K+ nanoparticle (SDKNP) 




in the TME. Significantly elevated K+ levels were found in the TME, with an average 
concentration of approximately 29 mM, matching the values found by the previous study. 








Photoacoustic (PA) imaging is a non-ionizing imaging technology that relies on the 
generation of acoustic waves from the absorption of electromagnetic energy due to the 
thermoelastic effect. Traditional photoacoustic imaging is usually performed using a 
combination of a nanosecond pulsed laser (to generate the electromagnetic energy) and 
an ultrasound transducer (to measure the thermoelastic waves that are generated). The 
nanosecond pulse width of the pulsed laser is important to satisfy the thermal and stress 
confinement parameters, which ensure that there is no significant heat diffusion or stress 
transmission away from the point of absorption 3. Satisfying these two requirements 
ensure the efficient generation of PA signals. While other forms of electromagnetic energy 
can be used, visible and near-infrared light (550 nm - 900 nm) are the most commonly 
used optical wavelengths for PA imaging 4. Excitation using the nanosecond light pulses 
in biological tissues generally results in a broadband acoustic signal (approximately tens 
of megahertz) with a low amplitude (< 10kPa) that can be picked up by the ultrasound 





Figure 1.1 Typical photoacoustic imaging setup. An acoustic coupling medium (such as water or ultrasound 
gel) is typically used between the ultrasound transducer and the sample being imaged to ensure good 
acoustic coupling.  
Traditional optical methods such as fluorescence, two-photon, and optical coherence 
tomography all require measuring the backscattered photons (or transmitted photons), 
which limits their in vivo imaging depth to several millimeters due to strong optical 
scattering in tissue. PA imaging, on the other hand, has been shown to be able to image 
structures/molecules centimeters deep in in vivo tissue 5. This is due to PA imaging 
measuring the acoustic signal output (not photons), which has orders of magnitude less 
scattering than visible/near-infrared light. Additionally, PA imaging does not rely on the 
ballistic regime of light (with notable exception of optically-focused PA imaging), further 
increasing its imaging depth capabilities 4. Hence, PA imaging has significantly more 
potential as an in vivo imaging tool than traditional optical approaches. PA imaging is said 
to provide optical contrast at the diffraction-limited high spatial resolution of ultrasound, 
with far superior imaging depths than other optical imaging technologies 6. 
The magnitude of the PA signal that is generated is directly dependent on the absorption 
















𝑃𝐴𝜆 = 𝛾𝜀𝜆𝜙𝜆𝐶 (1.1) 
where λ is the wavelength in nm, γ is the Grüneisen parameter, ε is the extinction 
coefficient, Ф is the optical fluence, and C is the concentration of the chromophore (in the 
case of visible light absorption). The Grüneisen parameter is a dimensionless parameter 
that is affected by temperature and can usually be ignored unless significant temperature 
changes are expected. The extinction (or absorption) coefficient is a parameter that is 
unique to each chromophore, or light-absorbing region of a molecule. Optical fluence 
reflects the magnitude of the excitation laser. Concentration reflects the quantity of the 
molecule that is generating the PA signal. Each molecule possesses a unique absorption 
spectrum, which is the basis on which methods like spectral unmixing, and subsequently 
blood oxygenation measurements are made. An example of the absorption spectra of 
blood (deoxyhemoglobin and oxyhemoglobin) is shown in Figure 1.2, with blood being 
one of the most dominant signals in biological tissue. This will be discussed in detail 





Figure 1.2 Absorption spectra of deoxyhemoglobin (Hb) and oxyhemoglobin (HbO2). Most PA imaging is 
conducted in the “optical imaging window” from 500 – 900 nm where the absorption of blood is low, allowing 
for better imaging depth in vivo. 
Photoacoustic imaging, in and of itself, is sensitive to several endogenous biological 
chromophores, such as deoxyhemoglobin, oxyhemoglobin, and melanin. The former two 
form an important application in photoacoustic imaging, where many studies have looked 
at quantifying blood oxygenation levels in vivo, with emphasis on both tumor and brain 
oxygenation measurements 6-11. Blood oxygenation is an important indicator for both 
measuring tumor hypoxia (and can potentially be used as an indicator for tumor response 
to treatment), as well as measuring functional brain information, similar to that conducted 
by BOLD (blood oxygenation level dependent) MRI 12. Blood oxygenation measurements 
are performed by exploiting the different absorption spectra of deoxyhemoglobin and 
oxyhemoglobin. By making at least two measurements at two different wavelengths, a 
ratio of the PA signal can be obtained which gives an indication of the blood oxygenation 
level. 
That being said, endogenous chromophore information can only go so far. As is typical 
to other imaging modalities as well, contrast agents and functional nanoparticles have 
been used in PA imaging to broaden its potential applications 13-15.  Contrast agents such 
as indocyanine green (ICG), methylene blue, and gold nanoparticles have been used to 
increase the signal-to-noise ratio (SNR) of PA imaging. These contrast agents are usually 
localized or targeted to a cell/tissue/organ of interest (such as sentinel lymph nodes, 
tumors, targeted antigens on cells), which provide enhancement of the PA signal of the 
target of interest 14,15. Alternatively, in addition to providing contrast, some of these 
nanoparticles have been used to provide molecular information in vivo 16,17, which forms 




imaging has been used in the monitoring of lithium treatments for bipolar disorder 18, 
measuring of tissue oxygenation using a lifetime-based approach 17,19-22, and measuring 
of tumor pH 16. 
In this thesis, I have employed the use of nanoparticles in PA imaging to achieve two 
broad purposes: (1) For contrast enhancement in cancer detection/diagnosis, and (2) For 
quantitative measurements of chemical parameters in the tumor microenvironment. This 
thesis is broken down into several chapters that will highlight my research into this field 
of nanoparticle-enabled photoacoustic imaging. 
Chapter 2 enters a brief discussion on multi-wavelength (spectral) unmixing and its role 
in nanoparticle-enhanced photoacoustic imaging. Here, I enter a brief discussion into the 
mathematical equations governing multi-wavelength unmixing as well. 
Chapter 3 discusses my development of a transient triplet differential method for 
background removal in photoacoustic imaging using phosphorescence-capable dyes. 
This technique showed significantly better signal-to-noise ratios and numerous other 
advantages over multi-wavelength unmixing. The technique was also demonstrated in 
vivo in a mouse tumor model to show its potential applications as a contrast enhancement 
technique in cancer research. 
Chapter 4 discusses my research into using an FDA-approved drug called clofazimine for 
prostate cancer diagnosis. Clofazimine is a lipophilic drug that specifically accumulates 
in macrophages. We hypothesized that due to tumor associated macrophages, 
clofazimine will accumulate in larger quantities in cancerous prostates than in normal 




contrast agent, we showed that there was indeed a higher accumulation in the cancerous 
prostate than in a normal prostate, which was detectable using both histology and PA 
imaging in an ex vivo setting.  
Chapter 5 discusses my contributions to the field of photoacoustic chemical imaging, 
specifically in that of in vivo potassium imaging. Photoacoustic chemical imaging focuses 
on the use of chemical nanosensors together with PA imaging for the purposes of in vivo 
measurements of chemical properties. Here, we demonstrated the ability to make 
quantitative measurements of potassium in an in vivo mouse tumor through the use of 
multi-wavelength unmixing. 
The dissertation is then ended with a summary of my contributions in the field of 
nanoparticle-enabled PA cancer imaging, and proposes some future steps that could be 









In this chapter, I will be taking a slight detour to explain an essential algorithm that is used 
extensively throughout my research. This method, known as multi-wavelength unmixing 
or spectral unmixing, is used to isolate the contributions of each identified chromophore 
from the PA signal as a whole 23,24. This method is widely used for most forms of 
quantitative PA imaging, including that of blood oxygenation measurements. Multi-
wavelength unmixing relies on an extension of equation 1.1, where instead of a single 
chromophore, we extend the contribution to the PA signal to take into account all the 
chromophores of interest. The extended equation is shown in equation 2.1. 
𝑃𝐴𝜆 = ∑ 𝛾𝑖𝜀𝑖,𝜆𝜙𝜆𝐶𝑖
𝑛
𝑖=0   (2.1) 
Making use of the difference in absorption spectra of each chromophore, equation 2.1 
can be used to determine the concentrations of each of the chromophores of interest. An 
example of this is shown in equation 2.2, where we assume the PA signal to arise from 3 
chromophores of interest, specifically Hb, HbO2, and a contrast agent “x”. 
𝑃𝐴𝜆 = 𝛾𝐻𝑏𝜀𝐻𝑏,𝜆𝜙𝜆𝐶𝐻𝑏 + 𝛾𝐻𝑏𝑂2𝜀𝐻𝑏𝑂2,𝜆𝜙𝜆𝐶𝐻𝑏𝑂2 + 𝛾𝑥𝜀𝑥,𝜆𝜙𝜆𝐶𝑥  (2.2) 
To simplify this equation, we make the assumption that the Grüneisen parameter, γ, is 




a good assumption assuming that the temperature of the sample remains constant. The 
later assumption, however, will affect the accuracy of the multi-wavelength unmixing with 
increasing errors at increasing depths due to the wavelength-dependent fluence 
attenuation of tissue. That being said, fluence compensation models are complex 25,26 
and is outside the scope of this thesis. It has been shown, however, that within shorter 
imaging depths (< 1cm), such as within a subcutaneous tumor, the error is of sufficiently 
low magnitude, allowing for quantitative imaging 16. Simplifying equation 2.2 based on 
these assumptions then yields equation 2.3. 
𝑃𝐴𝜆 = 𝑘(𝜀𝐻𝑏,𝜆𝐶𝐻𝑏 + 𝜀𝐻𝑏𝑂2,𝜆𝐶𝐻𝑏𝑂2 + 𝜀𝑥,𝜆𝐶𝑥)  (2.3) 
Here, k is the constant that includes the Grüneisen parameter and optical fluence. Based 
on equation 2.3, the extinction coefficients of Hb, HbO2, and contrast agent x are all 
known and measurable quantities, leaving only the concentrations of the 3 chromophores 
as unknowns. By making at least 3 separate measurements at different wavelengths, the 













]  (2.4) 
The PA signals are the measured signals, while the matrix with the extinction coefficients 
are all known. This equation can then be rearranged to obtain the concentrations of each 



















Using these concentration values, determining things like quantitative blood oxygenation 
measurements are then possible, by taking the ratios of the unmixed concentrations. For 
example, a typical blood oxygenation (SO2) measurement is as follows. 
%𝑆𝑂2 =  
𝑘𝐶𝐻𝑏𝑂2
𝑘𝐶𝐻𝑏𝑂2+𝑘𝐶𝐻𝑏
. 100%  (2.6) 
%𝑆𝑂2 =  
𝐶𝐻𝑏𝑂2
𝐶𝐻𝑏𝑂2+𝐶𝐻𝑏
. 100%   (2.7) 
As can be seen in equation 2.7, the constant k is then eliminated from equation 2.6, giving 
a quantitative measurement. It is of note that this is only possible with the assumptions 
on the Grüneisen parameter and optical fluence made earlier. This technique can then 
be extended for any number of chromophores, as long as an additional wavelength 
measurement is made for each additional unknown in equation 2.3. Notably, it is often 
the case that extra wavelength measurements (above what is strictly needed) are made 








Transient Triplet Differential Imaging for Background-Free 
Photoacoustic Imaging 
 
3.1 Brief Foreword 
This research work represents a method for PA contrast enhancement that relies on the 
use of phosphorescence dyes. The results have been published in the following article 
“Tan, J. W. Y.; Lee, C. H.; Kopelman, R.; Wang, X., Transient Triplet Differential (TTD) 
Method for Background Free Photoacoustic Imaging. Scientific Reports 2018, 8, 9290.” 
and most of the following text and figures are quoted verbatim from the above-mentioned 
publication. 
3.2 Abstract 
With the capability of presenting endogenous tissue contrast or exogenous contrast 
agents in deep biological samples at high spatial resolution, photoacoustic (PA) imaging 
has shown significant potential for many preclinical and clinical applications. However, 
due to strong background signals from various intrinsic chromophores in biological tissue, 
such as hemoglobin, achieving highly sensitive PA imaging of targeting probes labeled 
by contrast agents has remained a challenge. In this study, we introduce a novel 




reduction of tissue background signals. TTD imaging detects directly the triplet state 
absorption, which is a special characteristic of phosphorescence capable dyes not 
normally present among intrinsic chromophores of biological tissue. Thus, these triplet 
state absorption PA images can facilitate “true” background free molecular imaging. We 
prepared a known phosphorescent dye probe, methylene blue conjugated polyacrylamide 
nanoparticles, with peak absorption at 660 nm and peak lowest triplet state absorption at 
840 nm. We find, through studies on phantoms and on an in vivo tumor model, that TTD 
imaging can generate a superior contrast-to-noise ratio, compared to other image 
enhancement techniques, through the removal of noise generated by strongly absorbing 
intrinsic chromophores, regardless of their identity. 
3.3 Background 
Performed in a label-free manner, PA imaging can describe the morphological structures 
of biological samples based on the intrinsic optical absorption contrast among various 
tissues. As mentioned in the introduction, using optically absorbing contrast agents can 
make PA imaging more powerful and versatile. While PA imaging enhanced by such 
contrast agents has progressed significantly since its conception and has shown promise 
in probing not only structural but also molecular level information in biological samples in 
vivo, one of the main challenges is the presence of various intrinsic body chromophores 
that produce strong background signals 4,8. Here, we introduce a new technique called 
transient triplet differential (TTD) imaging which enables significant reduction of the 
background signal, regardless of the background chromophores. 
Ordinarily, when an organic molecule is excited, it enters an excited singlet state, followed 




of photons (fluorescence), release of heat (vibrational relaxation), product formation 
(photochemistry), and intersystem crossing (ISC) into the triplet state; the latter decays 
at a much slower rate, from microseconds to milliseconds, through phosphorescence 29. 
In the context of this study, we are focusing on the triplet state because of the presence 
of the long-lived triplet absorption peak that is only accessible for phosphorescent dyes. 
The process of generating a TTD signal is demonstrated in Figure 3.1, where a “pump” 
beam is used to excite the molecule from the ground state to the excited singlet state, 
which will then transition into the triplet state via ISC. Usually, the triplet state has a triplet 
absorption peak (λ2) that is spectrally well-shifted from the original singlet state absorption 
peak (λ1). By using a “probe” beam at this triplet state absorption peak, a PA signal will 
be generated by molecules that are in the triplet state at that time. Hence, a PA differential 
signal can be generated by comparing the PA signal at λ2 with and without a “pump” 
beam. Since only triplet state molecules of the phosphorescent dye will generate this PA 
signal, the differential signal will purely originate from the phosphorescent dye. This will 
allow for the removal of all background signals from any biological or other relevant 
chromophores, as these are non-phosphorescent. We define such a PA differential signal 
as the TTD signal. The technique introduced in this research work is similar to transient 
absorption spectroscopy (TAS), which uses both “pump” and “probe” beams,  except that 





Figure 3.1 Diagram demonstrating the generation of a TTD signal. The pump is defined as the laser used 
to excite the molecules from the ground to the triplet state, while the probe is the laser excitation used to 
measure the PA signal generated from the transition between the T2 and T1 states. 
Besides giving phosphorescence, molecules in the triplet state can also return to the 
ground state via quenching by other triplet state molecules, such as oxygen, which exist 
naturally in the triplet state 31. This process further limits the lifetime of the phosphorescent 
dyes in the triplet state, where it has been shown that the triplet state molecules will decay 
near-exponentially in time for phosphorescent molecules such as methylene blue (MB) 
20,32-34. The decay curves are affected by the oxygen concentration and this is an area of 
active research, where studies, including some focusing on PA methods, are being 
conducted to classify and characterize the change in the decay curves with respect to the 
oxygen concentration, with the end goal of mapping oxygenation levels in tissue 19,21,22,31-
35. 
In this study, we used methylene blue conjugated polyacrylamide nanoparticles (MBNP) 
by using the advantages from this nano-platform that has been developed extensively 
36,37.  MB is known to have a high quantum yield for ISC into the triplet state 1,38. MB can 
exist in two states, a monomer and a dimer state, with different ISC efficiencies. The dimer 
state has a triplet excited state lifetime (10-8 s) that is much shorter than that of the 




dependent on the concentration of the MB in the media and it is very challenging to 
approximate correctly the optimal concentration of free MB molecules in vivo (maximal 
monomer signal with minimal dimer signal). On the other hand, the monomer/dimer ratio 
in MBNP is not affected by the concentrations of the nanoparticles (NPs) because the MB 
to NP matrix ratio is always constant 39. As shown in Figure 3.2, the monomer/dimer ratio 
in MBNP was measured to be approximately 1:1. A constant monomer/dimer ratio 
facilitated by the polyacrylamide NPs makes the lifetime-based functional measurement 
quite robust, even in a complex in vivo environment.  In addition, MB is known to degrade 
into colorless “leuko-methylene blue” through enzyme reductions occurring in the 
bloodstream; while the NP matrix can effectively protect the MB from degradation in the 
presence of those enzymes 36. The nanoparticle matrix can be surface modified with a 
targeting moiety, such as an F3-peptide or other peptides 16,39-41. This allows the delivery 
of the NPs to specific tissues, or cells, in vivo 16,39,42,43. Besides that, certain sizes of NPs 
(50-100 nm), and specifically of these hydrogel NPs, are also known to accumulate well 
in tumors, due to the enhanced permeability and retention (EPR) effect 44. All these 
advantages associated with the use of the polyacrylamide nano-platform could be highly 





Figure 3.2 Absorption spectra of deoxyhemoglobin (Hb), oxyhemoglobin (HbO2), MBNP, and the blue ink 
as measured by a UV-VIS spectrophotometer. The approximately 660 nm peak corresponds to the 
monomer state while the 620 nm peak corresponds to the dimer state, with both states having an 
approximately equal absorption. The dashed black lines correspond to the three wavelengths used for 
spectral unmixing. The blue ink and the MBNP have a similar absorption profile in the sense that they show 
the same trend as compared to Hb and HbO2, that is they both have a higher absorption at 606 nm and 
660 nm and a lower absorption at 570 nm than Hb and HbO2.  
While triplet state imaging has been used as a method for measuring oxygen levels 
19,21,22,31-35, its application was not focused on producing background free PA imaging. We 
compare both a single wavelength contrast-agent enhanced image, and one of the more 
current PA background reduction techniques, called spectral unmixing or multi-
wavelength imaging 24,45,46, with our newly developed TTD imaging, for both phantom and 
an in vivo study. Our results suggest that the TTD imaging technique can produce 
background free PA images even in the presence of strongly competing chromophore 





3.4.1 MBNP Preparation 
All chemicals were purchased from Sigma-Aldrich unless otherwise noted. The MBNPs 
were prepared as in a previously reported method 38. All reactions were performed in the 
dark. The monomer solution was prepared as follows. DCMB-SE (European Molecular 
Precision Biotech, 5 mg dissolved in 100 μL of DMSO) was added into 0.93 mL of 
Phosphate Buffered Saline (PBS, pH 7.4) containing acrylamide (368 mg) and N-(3-
aminopropyl)-methacrylamide hydrochloride (Polysciences, 28 mg). The monomer 
solution was stirred for 2 hours at room temperature. Then, sodium dioctylsulfosuccinate 
(1.07 g) and Brij 30 (2.2 mL) were added into 30 mL of Hexane in a round bottom flask 
equipped with a stirring bar. After 30 min of argon flushing, the monomer solution was 
injected and flushed with argon for another 15 min. The radical polymerization was 
initiated by addition of 100 μL of N,N,N′,N′-tetramethylethylenediamine and 100 μL of 
ammonium persulfate (15 mg/100 μL in water), while stirring. After 2 hours, the hexane 
was evaporated with a rotary evaporator and the resulting MBNP NPs were suspended 
in Ethanol and transferred into an Amicon Stirred Ultrafiltration Cell equipped with a 
Biomax 300 kDa membrane. The solution was washed with ethanol and water several 
times to remove any unreacted monomers and surfactants. Then, the MBNP NPs water 
suspension was freeze-dried and stored at -20 oC.  
For surface modifications, the MBNP solution (50 mg/2.5 mL of PBS pH 7.4) was mixed 
with 4 mg of bifunctional Polyethylene glycol (MAL-PEG-SCM, 2kDa, Creative 
PEGWorks). After 30 minutes of stirring, it was washed with PBS (4 times) using Amicon 




(KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC, RS Synthesis) was added and stirred 
overnight. Then, cysteine (0.63 mg) was added and stirred for 2 hours to deactivate 
unreacted maleimide groups. The MBNP solution was washed with water and lyophilized. 
The MBNP was characterized by UV-VIS spectrometer (Shimadzu), fluorescence 
spectrometer (Horiba FluoroMax-3), and dynamic light scattering (Beckman Coulter). 
3.4.2 General PA Imaging Setup 
In all the experiments, the TTD signal was obtained by taking 3 separate PA signal 
measurements, specifically with a pump only laser, probe only laser, and a pump plus 
probe laser separated by a delay. The TTD signal is then obtained by subtracting the 
pump only and probe only measurements from the pump plus probe measurement. The 
general experimental setup for all the in vitro experiments is shown in Figure 3.3. 
 





3.4.3 Factors Affecting TTD Signal 
1) Delay time 
Using the setup shown in Figure 3.3, the TTD signal was measured for various delay 
times. The pump laser used was a tunable pulsed laser (Surelite OPO Plus, Continuum) 
pumped by the third harmonic of an Nd:YAG laser (Surelite, Continuum), with pulse 
duration of 5 ns, and tunable wavelengths in the range of 410-680 nm and 710-2500 nm. 
The probe laser was produced by an optical parametric oscillator (Vibrant B, Opotek, 
Carlsbad, CA, USA) pumped by the second harmonic output of a Nd:YAG pulsed laser 
(Brilliant B, Quantel, Bozeman, MT, USA), with pulse duration of 5.84 ns, and tunable 
wavelengths in the range of 680-950 nm and 1200-2400 nm. The transparent PVC tube 
was filled with 3.9 mg/mL MBNP and circulated using a peristaltic pump to ensure a 
continuous fresh supply of dye. An air pump was connected to the MBNP reservoir to 
maintain a constant level of oxygen. A section of the tubing was immersed in water to 
enable acoustic coupling with the ultrasound (US) transducer. A V312 cylindrically 
focused US transducer (Panametrics), with a central bandwidth of 10 MHz and focal 
length of 0.75 inch was used to detect the PA signal from the MBNP. The transducer was 
connected to an oscilloscope (TDS 540, Tektronix Inc) with a sampling rate of 250 MSa/s. 
The pump and probe wavelengths were fixed at 660 nm and 840 nm, respectively, while 
the delay time between the pump and the probe laser pulses was set to 0.02, 0.04, 0.06, 
0.08, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1.00, 1.20, 1.40, 
1.60, 1.80, 2.00, 2.50, 3.00, 3.50, 4.00, 5.00, 6.00, 7.00, 8.00, 9.00, and 10.00 µs using 




times, and the mean of the recordings were taken to minimize the noise due to the random 
fluctuations in the signal. The data was processed using Matlab. 
2) Oxygen 
To alter the oxygen concentrations, an additional tube connected to a gas (oxygen or 
nitrogen) tank was added to the peristaltic pump reservoir. Additionally, an oxygen meter 
(Microx TX3, Presens) was immersed into the reservoir to continually monitor the oxygen 
levels during the experiment. Three different oxygen levels were maintained, specifically 
at low oxygen (5-10%), air oxygen (21%), and medium oxygen (45%) concentrations. The 
low oxygen level was maintained by continually adding nitrogen gas into the reservoir, 
which resulted in an oxygen level of approximately 5-10%. The air oxygen level was 
maintained by continuously pumping air into the reservoir using the air pump. The 
medium oxygen level was maintained by adding both air using the air pump and oxygen 
using the oxygen tank and balancing the gas pressures to form a stable oxygen level. 
The TTD signals for 7 delay times of 0.1, 0.2, 0.5, 1.0, 2.0, 3.0, and 5.0 µs were measured 
at each oxygen level for a MBNP concentration of 2.0 mg/ml. 
3) MBNP concentration 
The delay time was fixed at 0.2 µs. The MBNP concentration was varied between 0.005 
mg/ml and 3.5 mg/ml. 
4) Pump and probe laser energy 
The concentration of MBNP was diluted to 0.6125 mg/ml in order to attempt saturation of 
the TTD signal within the maximum permissible exposure (MPE) limit. The energy of the 




energy of the probe laser was varied in the range of 1.6-9.5 mJ/cm2. The simulated energy 
vs penetration depth at each wavelength for each tissue was calculated using the 
effective attenuation coefficient, µeff, and Beer’s law, as shown in equations (3.1) and 
(3.2). 
𝜇𝑒𝑓𝑓 = √3𝜇𝑎(𝜇𝑎 + 𝜇𝑠′)   (3.1) 
𝜙(𝑧) = 𝜙(0)𝑒−𝜇𝑒𝑓𝑓𝑧    (3.2) 
where µa is the absorption coefficient (cm-1), µs’ is the reduced scattering coefficient (cm-
1), and µ(z) is the energy at depth z. The values for µa and µs’ were obtained from 
previously published results 2,47-49. 
3.4.4 CNR and Sensitivity 
To examine CNR and sensitivity, the concentration was varied in the range of 0.001-2.0 
mg/ml for the MBNP with the same conditions as before. Two sets of concentration 
measurements were conducted, one with the MBNP suspended in distilled water, and the 
other with the MBNP suspended in 5% human blood to act as biological noise. The PA 
signals were compared between the three different methods, including 1) the single-
wavelength (660 nm) PA amplitude increase due to the increasing MBNP concentration, 
2) the spectrally unmixed signal, and 3) the TTD signal. The 660 nm PA amplitude 
increase was measured by subtracting the PA signal for a given MBNP concentration by 
the PA signal for a control sample where the concentration of MBNP is zero. The 
spectrally unmixed signal was calculated by measuring the PA signals at the three 
wavelengths of 570 nm, 606 nm, and 660 nm, respectively. In this case, the spectrally 




spectra of Hb and HbO2, the relative concentration of the MBNP in the PA image can be 
calculated using the simultaneous equations (3.3) - (3.5). 
𝑘([𝐻𝑏]𝑎𝐻𝑏@570𝑛𝑚 + [𝐻𝑏𝑂2]𝑎𝐻𝑏𝑂2@570𝑛𝑚 + [𝑀𝐵𝑁𝑃]𝑎𝑀𝐵𝑁𝑃@570𝑛𝑚) = 𝑃𝐴570𝑛𝑚 (3.3) 
𝑘([𝐻𝑏]𝑎𝐻𝑏@606𝑛𝑚 + [𝐻𝑏𝑂2]𝑎𝐻𝑏𝑂2@606𝑛𝑚 + [𝑀𝐵𝑁𝑃]𝑎𝑀𝐵𝑁𝑃@606𝑛𝑚) = 𝑃𝐴606𝑛𝑚 (3.4) 
𝑘([𝐻𝑏]𝑎𝐻𝑏@660𝑛𝑚 + [𝐻𝑏𝑂2]𝑎𝐻𝑏𝑂2@660𝑛𝑚 + [𝑀𝐵𝑁𝑃]𝑎𝑀𝐵𝑁𝑃@660𝑛𝑚) = 𝑃𝐴660𝑛𝑚 (3.5) 
where k is a constant depending on the Grüneisen parameter of the tissue, the light 
fluence, and the sensitivity of the imaging system, [x] is the concentration of chromophore 
x, ax@λ is the absorption coefficient of chromophore x at wavelength λ, PAλ is the 
photoacoustic signal at wavelength λ nm. 
A constraint where the estimated concentrations had to hold positive values was imposed 
on the spectral unmixing algorithm. These equations also assumed a constant fluence 
level at the different laser wavelengths. 
The TTD signal is obtained using the method specified in the beginning of the methods 
section. The CNR was measured by taking the PA signal for the given MBNP 
concentration and subtracting it from the PA signal at zero MBNP concentration, and 
dividing it by the standard deviation of the five measurements made for each 
concentration. The sensitivity was classified as the MBNP concentration before which the 
PA signal fell below the noise level. 
3.4.5 Effectiveness in Different Background Noises 
To study the effects of background noise, various samples were prepared, specifically, 




blue ink, 2.0 mg/ml MBNP in 5% blood and 5% GNP, 5% blood, and distilled water. The 
GNP was obtained from IMRA America, Inc. The percentages listed are all measured by 
volume. The samples were prepared by taking a stock solution of 25 mg/mL MBNP and 
diluting it in PBS together with the other solutions to get the required concentrations. The 
PA measurements at the five separate wavelengths, 570 nm, 606 nm, 660 nm, 840 nm, 
and 660 nm + 840 nm, were obtained. The TTD and SU signal were obtained in the same 
way as previously mentioned. 
3.4.6 Validation on an In Vivo Mouse Tumor Model 
All procedures on live animals were performed in accordance with institutional guidelines 
and approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Michigan. 9L glioma cells (ATCC) were cultured in RPMI 1640 media and 
supplemented with 10% fetal bovine serum and 1% antibiotic-antimycotic. 5-week old 
athymic nude fox/NU (Envigo) were subcutaneously injected with approximately 106 
glioma cells (ATCC) in a 100 µL suspension of culture media. The tumor was allowed to 
grow for 2-3 weeks until it reached approximately 1 cm in diameter. For imaging, a setup 
similar to Figure 3.3 was used, where instead of coupling the beam to an optical fiber, a 
freely propagating beam was used. A commercially available research ultrasound 
platform (V1, Verasonics, Kirkland, WA) using a high frequency linear array transducer 
with central frequency of 11.25 MHz (CL15-7, Philips, Andover, MA) was used to acquire 
the ultrasound and PA images from the mice. A delay time of 0.5 µs between the pump 
and the probe lasers was used. The mouse was placed under anesthesia using 1-2% 
isoflurane mixed with oxygen for the duration of the experiment and intravenously injected 




wavelengths, i.e. 570 nm, 606 nm, 660 nm, 840 nm, and at 660 nm + 840 nm, were 
obtained for time points 0 (before the injection), 1 (right after the injection), 30, 60, and 90 
minutes. To improve the SNR of the images, the images were averaged 50 times. The 
TTD and SU signals were obtained in the same way as previously mentioned. 
3.5 Results and Discussion 
3.5.1 TTD Signal for MBNP 
Figure 3.4 demonstrates the process of obtaining the TTD signal. Figure 3.4A shows the 
superimposed waveforms (PA signals) obtained for the pump (660 nm), probe (840 nm), 
and pump plus probe (660 nm + 840 nm) excitations. Here, there is a noticeable increase 
in the signal amplitude for the second peak in the pump plus probe waveform, which 
corresponds to the waveform shown in Figure 3.4B. This increase in signal is the TTD 
signal. The used wavelengths of 660 nm and 840 nm are the peak singlet and triplet state 
absorption wavelengths, respectively, for the MBNP, which is shown in Figure 3.5. Since 
the delay time used is on the order of 1 µs, the TTD signal is solely due to MB in the 
monomeric state as all the MB in the dimer state would have returned to the ground state 
due to their much shorter triplet state lifetime (10-8 s). Previous works have identified the 
monomeric MB absorption peak at 660 nm and the triplet absorption peak at 840 nm 1, 





Figure 3.4 Generation of the TTD PA signal. (A) Superimposed PA signals from the individual wavelength 
measurements for the pump (660 nm), probe (840 nm), and from the pump plus probe (660 nm + 840 nm) 
wavelengths. (B) TTD signal obtained by subtracting the individual 660 nm and 840 nm signals from the 
660 nm + 840 nm signal for a 2.0 mg/mL MBNP sample in a visible-light transparent tube with a 0.5 µs 
delay time. 
 
Figure 3.5 Wavelength dependence of the MBNP as measured by PA imaging. Colorbar indicates the 
normalized TTD signal. The peak TTD signal occurs at 660 nm (pump) and 840 nm (probe) which are the 




3.5.2 Factors Affecting TTD Imaging 
We looked at the effects of multiple parameters on the TTD signal of MBNP, specifically 
the delay time between the pump and probe lasers, oxygen level, MBNP concentration, 
and the pump and probe laser energy. Two other factors that also affect the TTD signal, 
that of the laser wavelengths and the monomeric-dimer ratio of the MBNP, are not 
discussed in Figures 3.6 and 3.7 as the former has already been determined for 
monomeric MB, while the latter is fixed in the case of the MBNP.  
Figure 3.6A demonstrates the relationship between the TTD amplitude and the delay time 
for MBNP from 0.02 µs to 10 µs. The TTD amplitude follows a decaying exponential 
relationship with increasing delay time as reported in previous studies 21,33.  From Figure 
3.6B, we see that the slope of the exponential decay of the TTD amplitude increases as 
the oxygen concentration increases. As mentioned previously, since oxygen exists 
naturally in the triplet state, the higher the concentration of oxygen, the more triplet oxygen 
molecules are available to quench the triplet state MB molecules. This leads to a faster 
decay in the TTD amplitude as the concentration of oxygen increases. At low oxygen 
levels (5-10%), we see an almost linear relationship between the TTD amplitude and the 
delay time, which has been previously reported 22. Figure 3.6C shows that the TTD 





Figure 3.6 Normalized TD signal for (A) Varying delay times, with exponential decay curve fit of r2 = 0.9485, 
(B) Low (5-10%), air (21%), and medium (45%) oxygen levels of the MBNP sample solution, and (C) 
Varying [MBNP] in PBS. Error bars indicate the standard deviation of the signal for 5 repeated 
measurements. 
Theoretically, we expect the TTD amplitude to vary linearly with pump and probe energy. 
The greater the pump energy, the greater the amount of MB molecules that are pumped 
into the triplet state, and hence the greater the TTD amplitude. Similarly, the greater the 
probe energy, the greater the amount of triplet state molecules that are excited, and hence 
the greater the TTD amplitude. This linear relationship only holds until saturation, since 
the maximum TTD amplitude is dependent on both pump and probe energies, and one 
or the other will act as a limiting factor. In the case of excess probe energy, the limitation 
factor becomes the number of triplet state molecules that are available to be excited, 
which is determined by the pump energy. In the case of excess pump energy, the 
limitation factor becomes the energy available to excite the triplet state molecules, which 
is determined by the probe energy.  
Figure 3.7A shows the general trend: As the pump and probe energy increases, the TTD 
amplitude increases. Figure 3.7B shows the relationship between the TTD amplitude and 
probe energy for various fixed pump energies. For low probe energies, the TTD amplitude 
increases approximately linearly with pump power before reaching a plateau. As the 
probe energy increases, the pump energy level at which the TTD amplitude plateaus 
increases. At the highest probe energy used, the TTD amplitude never reaches a plateau 
within the experimental range of pump energy values used. This means that within the 
experimental values used, the MBNP is never fully saturated. Looking at the two plateau 
values for 4.3 mJ/cm2 and 6.4 mJ/cm2 probe energies, the TTD amplitude decreases by 




the TTD amplitude and the probe energy. Figure 3.7C shows a similar relationship 
between the TTD amplitude and probe energy for various fixed pump energies. Looking 
at the two plateau values for 5.7 mJ/cm2 and 7.7 mJ/cm2 pump energies, the TTD 
amplitude decreases by 32% for a 26% decrease in pump energy. Figure 3.7D shows the 
simulated penetration depth for TTD imaging in the skin and breast using available optical 
absorption and scattering information from literature 2,47-49. These two tissue types are 
shown to demonstrate the feasibility of using TTD imaging in, for example, skin and breast 
cancer related diseases. Here, the estimated maximum penetration distance for TTD 
imaging (based on the maximum permission exposure limit of 20 mJ/cm2) is 
approximately 3.9 mm for the skin and 12 mm for breast tissue, where, in both cases, the 
pump wavelength (660 nm) acts as the limiting energy factor, due to the fact that 660 nm 





Figure 3.7 Energy dependence of the TTD amplitude, with (A) showing the normalized TTD amplitude 2-
D plot vs pump and probe energy, (B, C) showing the normalized TTD amplitude vs pump/probe energy at 
4 fixed probe/pump energy levels respectively, and (D) showing the simulated energy vs penetration depth 
for skin and breast tissue with initial fluence of 20 mJ/cm2 (maximum permissible exposure limit). Colorbar 
in (A) shows the normalized intensity based on the maximum TTD intensity. The black lines (solid – 660 
nm, dashed – 840 nm) in (D) indicate the minimum energy required for TTD imaging for the respective 
wavelengths, derived from (A) where the minimum pump energy is taken as 1.6 mJ/cm2 and the minimum 
probe energy as 2.7 mJ/cm2. 
3.5.3 Contrast-to-Noise Ratio and Sensitivity 
In terms of contrast-to-noise ratio (CNR), Figures 3.8A-C show that TTD imaging clearly 
has the superior CNR at all detectable concentration levels, followed by spectral unmixing 
(SU), and subsequently by the MBNP contrast agent at 660 nm. The CNR for TTD 
imaging is approximately double that of SU at all concentrations, and triple that of the 
MBNP contrast agent alone. Figures 3.8D-F show the sensitivity of the various imaging 
techniques for MBNP in the presence of 5% blood, while Figures 3.8G and 3.8H show 
the sensitivity of MBNP in the presence of water. Here, we found that TTD imaging has 
approximately the same sensitivity levels in both blood and water, being able to detect up 
to 0.05 mg/mL of MBNP. This high sensitivity level is significant as it allows for its potential 
use in vivo, where this concentration would involve a 400 times dilution of a typical 
injection volume using 20 mg/mL MBNP. This means that even if the target area receives 
a concentration of only 1/400 of the injected MBNP, the sensitivity offered by TTD imaging 
will still be high enough to detect it. In addition, TTD imaging demonstrates a 10x superior 
detection sensitivity compared to that of just using the MBNP contrast agent, and shows 
detection sensitivity similar to that of SU. The TTD amplitude itself is also unaffected by 
the blood, as can be seen from having similar PA amplitudes for the various 
concentrations in blood and in water (Figures 3.8F and 3.8H). While TTD imaging seems 
to have a similar sensitivity to SU, the body has many more additional chromophores 




oxyhemoglobin (HbO2), such as melanin, lipids, etc., which will make SU significantly 
more challenging in vivo.  
 
Figure 3.8 CNR and sensitivity measurements comparing 3 methods; MBNP, as a contrast agent, taken at 
its absorption peak of 660 nm (A, D, G), spectral unmixing (SU) (B, E), and TTD imaging (C, F, H). The 
CNR in (A-C) where measured by taking the difference between the PA signal at a given concentration and 
the PA signal at zero concentration of MBNP, divided by the maximum noise fluctuation. Figures (D-H) 
show the minimum detectable concentration of MBNP (sensitivity) which are labeled by the red circles. 
Figures (A-F) corresponds to MBNP suspended in 5% blood to mimic physiological conditions, while (G, 
H) are suspended in water. 5% blood was used as most biological tissues contain between 0-5% of blood 
by volume 2. Spectral unmixing was not conducted for the MBNP in water due to the absence of 
deoxyhemoglobin and oxyhemoglobin in the sample. Error bars indicate the standard deviation of the signal 
for 5 repeated measurements. 
3.5.4 Effectiveness in Different Background Noises  
Figure 3.9A shows the PA amplitudes of the six different samples at the 5 chosen 
wavelengths reflecting the spectroscopic absorption property of each sample. As 
expected, samples with 2.0 mg/ml MBNP show a higher absorption at 660 nm as 




significantly increases the absorption at 570 nm, 606 nm, and 660 nm and acts as an 
increased background noise at those wavelengths. Samples containing 5% whole blood 
show a higher absorption at all the wavelengths except at 660 nm which is dominated by 
the MBNP signal. The sample containing 5% gold nanoparticles (GNP) with a peak 
absorption wavelength at 532 nm acts as the second unknown chromophore, showing a 
small increase in PA amplitude at the 570 nm and the 606 nm wavelengths due to residual 
optical absorbance. Figure 3.9B shows that there is no statistical difference between the 
TTD amplitude obtained for the four samples containing MBNP, which suggests that the 
TTD amplitude is independent of the background chromophores present in the sample. 
Importantly, the two control samples did not show any TTD signal, which demonstrates 
the potential of TTD imaging for removing background noise. This is contrasted with the 
SU method in Figure 3.9C, which shows a baseline signal even in the absence of any 
MBNP. Furthermore, the SU method shows a significantly increased error in the 
estimated MBNP concentration for the sample containing the blue dye, as it was 
indistinguishable by the SU algorithm from the MBNP, since the blue dye and the MBNP 
have similar absorption profiles for the chosen wavelengths, as shown in Figure 3.2. The 
SU method also shows a significant difference for the 2.0 mg/mL MBNP in 5% blood 
sample, which is probably due to errors in the unmixing algorithm, arising from ignoring 
all other chromophores beyond the MBNP, Hb, and HbO2. These unaccounted-for 
chromophores include water as well as the transparent PVC tubing used to hold the 
sample. This result on phantoms demonstrates the ability of TTD imaging to isolate the 




presence of these chromophores is almost inevitable for any in vivo imaging application. 
A similar example in the presence of a muscle tissue background is shown in Figure 3.10. 
 
Figure 3.9 Data comparing the TTD imaging method and SU for six different samples, including 2.0 mg/ml 
MBNP, 2.0 mg/ml MBNP in 5% whole blood, 2.0 mg/ml MBNP in 5% whole blood plus 0.1% blue ink, 2.0 
mg/ml MBNP in 5% whole blood and 5% gold nanoparticles (GNP), 5% whole blood, and water. Both the 
5% blood and the water samples act as the controls. (A) Normalized PA amplitude at 5 separate 
wavelengths. (B) Normalized TTD amplitude. (C) Relative MBNP concentration measured by spectral 
unmixing. Error bars indicate the standard deviation of the signal for 5 repeated measurements. ** 
represents p<0.01, and *** represents p<0.001 for a t-test with hypothesis that the normalized TTD 





Figure 3.10 PA imaging results on a rat muscle where a drop of MBNP and a drop of blue ink were added 
to the top surface of the muscle tissue (MBNP at the left; blue ink at the right). Here, the PA images 
superimposed on a gray-scale ultrasound image are shown for (A) the raw MBNP signal taken at its 
absorption peak of 660 nm, (B) the spectral unmixed signal detailing the estimated concentration of MBNP, 
and (C) the TTD image. The white dotted line details the muscle tissue outline. (D) shows the region-of-
interest (ROI) selected for quantitative analysis (outlined in red), centered at the maximum intensity with 
size chosen to match expected sample drop size. Colorbar shows the normalized intensity based on the 
maximum intensity within each imaging method. (E) shows the normalized signal amplitude for the selected 
ROI for the three different methods. Error bars indicate the standard deviation within each selected ROI. 
*** represents p<0.001 for a t-test with hypothesis that the normalized signal amplitude for the selected ROI 
is equal to that of the muscle (control) ROI. 
3.5.5 Validation on an In Vivo Mouse Tumor Model  
To demonstrate the applicability of the TTD technique in vivo, we show time-lapse images 
of a subcutaneous mouse tumor model. F3-conjugated MBNPs were injected 
intraveneously and preferentially accumulate in the tumor through both F3-targeting 42,43 
and the EPR effect. Figures 3.11A-C show the superimposed, time-lapsed ultrasound and 
PA images of the tumor at a single wavelength of 660 nm (Figure 3.11A), MBNP 




The image at time 0 shows the tumor before the MBNP injection, while the image at time 
1 shows the tumor immediately after injection, while 30, 60, 90 mins designate the times 
after the injection, respectively. Here, we see that at time 0, the TTD image shows an 
almost zero signal, with increasing signals as time progresses, due to accumulation of 
the MBNP in the tumor. In contrast, we see some baseline signal at time 0 for both the 
660 nm and SU image, although it is significantly smaller in the case of the SU image, 
and a similar increase in signal as time progresses. There is peak accumulation of the 
MBNP in the tumor at around 30-90 mins, where the signals in all 3 imaging methods are 
relatively consistent. It should be noted that most of the TTD signal is localized within the 
tumor, while there are background signals for the other two methods. However, the 
majority of the TTD signal is located towards the upper region of the tumor, which is most 
likely an indicator of the energy constraints of this technique. Figure 3.11D shows the 
normalized mean tumor signal based on the region-of-interest (ROI) shown in Figure 
3.11A. Figure 3.11E shows the change in the mean tumor signal with respect to the mean 
tumor signal at time 0 min. Figures 3.11D and 3.11E together show the superiority of the 
TTD imaging method in removing background signals compared to the other two 
methods, as demonstrated by the low signal in the tumor at times 0 and 1 min, and the 





Figure 3.11 In vivo time-lapse images of a mouse subcutaneous tumor model using: (A) a single 
wavelength at 660nm, (B) MBNP concentration as determined via SU, and (C) TTD imaging. Each PA 
image is superimposed on the B-scan ultrasound image in gray scale. Time scales indicate the time after 
MBNP injection, with 0 min being just before the injection. The ROI shown at time 0 min in (A) was chosen 
to encapsulate the whole tumor except the tumor boundaries, which typically generate a much larger PA 
signal compared to the rest of the tumor. The colorbar shows the normalized intensity based on the 
maximum intensity within each imaging method. (D) Normalized mean tumor signal as a function of time 
within the ROI indicated in (A). (E) Mean tumor signal change based on the mean tumor signal at time 0 
min. M1 and M2 indicates two separate animal experiments that were conducted. The figures shown in 
panels (A-C) are from M1. 
3.6 Discussion 
While TTD imaging is dependent on many different parameters, most of the parameters 
can be controlled or accounted for so as to ensure a consistent TTD signal. The pump 
and probe laser wavelengths, delay times, and monomer/dimer ratio of the MBNP can be 
controlled and optimized so as to maximize the TTD signal. The first two are modifiable 
parameters of the lasers while the monomer/dimer ratio can be controlled by modifying 
the composition of the MBNPs. The oxygen dependence of the TTD signal can be 
reduced by using a short delay time, during which the TTD signal can be assumed to be 
approximately invariant to oxygen, as demonstrated in Figure 3.6. That being said, the 




19,33, enabling both contrast enhancement and oxygen measurements. The energy 
dependence of the TTD signal is harder to control, due to effects such as light scattering 
and absorption. To minimize energy effects on the TTD signal, an energy level that 
saturates the TTD contrast agent should be used, if possible. If a TTD contrast agent can 
be designed such that it has a lower saturation energy, it could potentially minimize the 
energy dependence of the TTD signal. In addition, since the TTD signal follows a linear 
relationship with concentration, the amplitude of the TTD signal should be a direct 
indicator of the concentration of the MBNP, with deviations only resulting from differences 
in energy and oxygen levels. Despite the TTD imaging being limited by its energy 
requirements, the effective imaging depths offered by the current design of the MBNP are 
estimated as 3.9 mm for skin and 12 mm for breast tissue. In addition, we have 
demonstrated that we can obtain the TTD signal for an imaging depth of at least 5 mm in 
an in vivo mouse model. 
It should be noted that the microsecond scale of the delay time between the pump and 
the probe light pulses can potentially lead to an overlap of the PA signals from the two 
pulses, since acoustic waves travel at a much slower velocity than light waves. This could 
potentially cause problems such as a reduction in the dynamic range of the system due 
to the increase in the maximum amplitude of the combined signal. In addition, interference 
between the pump and the probe PA signals could occur. A potential solution to this would 
be to design a TTD contrast agent with a longer delay time such that the two PA signals 
do no overlap. An example of a TTD contrast agent such as this would be the oxyphor 
G2 dye which has a lifetime of up to 250 µs 21. It should be noted, however, that while this 




longer lifetime also means a longer image acquisition time which could be a problem for 
time variant systems, for example when the body motion of the imaging subject cannot 
be ignored. The above-mentioned dynamic range issue can also be solved by calculating 
the TTD signal in an analog circuit before conversion into a digital system, so as to 
maximize the dynamic range of the system in detecting the TTD signal. 
While we have used MBNP for this proof-of-concept study, there are in fact many other 
organic dyes capable of phosphorescence that are available for use 29. Organic dyes, 
while only forming a subset of PA contrast agents, hold a better chance for clinical 
translation due to their better biocompatibility and potentially less toxicity. In fact, we 
chose to use MB for this study as it is both an FDA-approved dye, and a very commonly 
used contrast agent. That being said, there has been research into triplet states for 
inorganic dyes, such as gold nanoclusters, although their triplet state absorption was not 
studied extensively 50. This TTD technique is unique in the sense that it enhances contrast 
agents that are already widely used in PA imaging to realize molecular level studies of 
cancer and a variety of other diseases (with MB itself being a common PA contrast agent). 
In particular, we expect this method to be widely applicable and to have a broad impact 
in the cancer imaging field, especially for the targeted imaging of superficial or quasi-
superficial cancers, such as skin, head and neck, gastrointestinal track, and urethral track 
cancers. In this study, we have demonstrated the feasibility of achieving this, using our 
tumor-targeting F3-peptide conjugated MBNP for subcutaneous tumor imaging. However, 
since this TTD technique relies on triplet state absorption, there could be potential 
damage to the cells if the concentration of the phosphorescent dye and the laser energy 




and the triplet state oxygen, leading to the formation of reactive oxygen species. Because 
the main application that we are envisioning for this method is in targeted imaging of 
cancer, this potential biological damage to the surrounding cancer cells during TTD 
imaging could actually be beneficial. In other words, the TTD-based PA imaging powered 
by MBNP could be a theranostic platform for both diagnosis and treatment of cancer. 
3.7 Conclusion and Future Steps 
In summary, the experimental results on MBNP demonstrate the ability of TTD imaging 
to provide background free PA images in a way that was not achieved by the other two 
previously established image enhancement methods. TTD imaging has a 3x superior 
CNR and 10x higher sensitivity than the method using a single-wavelength contrast agent 
enhanced image. Furthermore, TTD is independent of the background chromophores, 
while SU is significantly affected by background chromophores with optical absorption 
spectra similar to those of the chromophore of interest. Unlike SU, TTD imaging does not 
require knowledge of the spectra of the background chromophores in order to remove 
them from the image signal. In addition, there will be a non-zero baseline signal for SU, if 
additional wavelength measurements are not performed to account for all the 
chromophores present in the sample. While not shown in the results, in theory, the TTD 
method will allow for the use of multiple contrast agents without having to worry about 
spectral overlapping. As long as one of the parameters (pump wavelength, probe 
wavelength, or lifetime) are different, the signals from each respective dye can be 
isolated. Lastly, SU also takes a significantly longer post-processing time due to the 
calculations needed to be performed, and can also potentially take a longer acquisition 




While SU is an established processing tool for most optical imaging techniques, TTD 
imaging could prove more useful in complicated biological systems with many different 
competing chromophores, where the above ability to remove the contributions of all these 
chromophores and isolate the TTD signal from the phosphorescence dye can be highly 
valuable in applications such as in molecular imaging of cancerous tissue, in which we 
have demonstrated the feasibility of accomplishing using our F3-conjugated MBNP in an 











Photoacoustic Imaging of Clofazimine Hydrochloride Nanoparticle 
Accumulation in Cancerous vs Normal Prostates 
4.1 Brief Foreword 
This research work represents a method for PA contrast enhancement of prostate cancer 
using a macrophage-targeting FDA approved drug called clofazimine. The results have 
been published in the following article: 
“Tan, J. W. Y., Murashov, M. D., Rosania, G. R. & Wang, X. Photoacoustic imaging of 
clofazimine hydrochloride nanoparticle accumulation in cancerous vs normal prostates. 
PLOS ONE 14, e0219655, doi:10.1371/journal.pone.0219655 (2019)” 
and most of the following text and figures are quoted verbatim from the above-mentioned 
publication. 
4.2 Abstract 
Prostate cancer was the most common form and had the second highest death rate of 
male cancer in the United States in 2015. Current diagnosis techniques, such as prostate-
specific antigen tests, transrectal ultrasound scans, and biopsies, are often inconclusive, 
and in the latter case, invasive. Here, we explore the use of clofazimine hydrochloride 
nanoparticles (CFZ-HCl NPs), a repurposed formulation from an FDA-approved 




cancer due to its macrophage-targeting capabilities and high optical absorbance at 495 
nm. Using a transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model, 
our results indicate a preferential accumulation of intravenously injected CFZ-HCl NPs in 
cancerous prostates over normal prostates. Differences in accumulation of CFZ-HCl NPs 
between cancerous and normal prostates were determined using a two-wavelength 
unmixing technique via ex vivo photoacoustic imaging. Thus, intravenous injection of 
CFZ-HCl NPs leads to differences in the interactions of the particles with cancerous vs 
normal prostates, while allowing for photoacoustic detection and analysis of prostate 
cancer. These findings could lead to the development of a new noninvasive technique for 
the detection and monitoring of prostate cancer progression in an animal model that can 
potentially be translated to human patients. 
4.3 Introduction 
Prostate cancer was the leading form of cancer among men (183,529 new cases) and 
had the second highest death rate for cancer among men in the United States (28,848 
deaths), as reported in 2015 51. For many years, prostate-specific antigen (PSA) blood 
tests and digital rectal examinations (DREs) have been the first line of detection for 
prostate cancer. While PSA tests act as an indicator for the stage and prognosis of the 
prostate cancer, PSA levels can vary significantly depending on factors such as age, 
lifestyle, and other medication 52-54. Therefore, this test is rarely used on its own as a 
definitive indicator of prostate cancer. Abnormal readings in the PSA levels or suspicious 
nodules found through DREs will usually be followed up with a transrectal ultrasound scan 
(TRUS), which is usually complimented with a biopsy due to the fact that TRUS by itself 




procedures that can cause potential complications and have significant false-negative 
rates (e.g. 15% - 31% for the traditional sextant core biopsies) 57-63. Magnetic resonance 
imaging (MRI) has also been used in the assessment of prostate cancer 64-67. However, 
patients with prostates that are suspected of being cancerous through MRI assessment 
still typically require a biopsy for confirmation of the prostate cancer 64,65,68. Thus, there is 
a need to develop novel techniques for detecting prostate cancers through noninvasive 
means. 
In this study, we explored the differences in the interaction of clofazimine hydrochloride 
nanoparticles (CFZ-HCl NPs) 69 with normal and tumor bearing prostates, using the 
transgenic adenocarcinoma of the mouse prostate (TRAMP) animal model 70. CFZ is a 
red-pigmented dye and a weakly basic, FDA-approved, orally administered, 
antimycobacterial agent that is recommended by the World Health Organization as a 
treatment for leprosy and multidrug resistant tuberculosis 71-79. In patients, CFZ exhibits 
atypical pharmacokinetic properties that result in accumulation and stabilization in tissue 
macrophages of solid drug biocrystals that resemble a hydrochloride (HCl) salt form of 
the drug 80-85. These CFZ-HCl biocrystals were determined to be biocompatible, stable, 
long-lived, relatively non-toxic, and anti-inflammatory 86,87, which led to the development 
of a biomimetic formulation of CFZ-HCl NPs  for parenteral administration 69. Importantly, 
Murashov et al. demonstrated that these CFZ-HCl NPs preserved the majority of 
characteristics of CFZ-HCl biocrystals, including targeting and accumulating inside 
macrophages in vitro and in vivo 69. Thus, the presence of tumor associated macrophages 
(TAM), including those in prostate tumors 88,89, makes CFZ-HCl NPs a potentially useful 




In addition to the functional and therapeutic properties, CFZ-HCl NPs have also been 
shown to exhibit a strong signal in the Cy5 fluorescence range (650 nm excitation/670 nm 
emission) and peak optical absorbance at 495 nm 69,90. In contrast to the free dye CFZ, 
CFZ-HCl NPs have a redshifted peak optical absorbance at 495 nm (compared to 450 
nm for free dye CFZ), making it more suitable for biological optical applications due to the 
reduced interference from endogenous chromophores, such as blood at this longer 
wavelength 91. This strong optical absorbance makes it a suitable contrast agent to be 
used with photoacoustic (PA) imaging. Notably, we have previously demonstrated the 
capabilities of CFZ as a PA contrast agent for potential applications in arthritis 91. 
In this study, we hypothesized that intravenous (IV) administration of the biomimetic 
formulation of CFZ-HCl NPs will result in differences in distribution of the particles in 
cancerous prostates and in normal prostates, which will be measurable via PA imaging. 
By correlating the PA signals with histopathology and quantitative drug analysis of 
nanoparticle distribution in the prostates, our results clearly showed a higher 
accumulation of CFZ-HCl NPs in cancerous prostates over normal prostates, which led 
to greater PA signals using a multiple wavelength PA image analysis technique. Thus, 
CFZ-HCl NPs may offer a noninvasive probe using PA imaging for the detection and 
longitudinal assessment of prostate cancer progression in an animal model with potential 





4.4.1 IV Injection of CFZ-HCl NP in Mice 
Animal care was provided by the Unit for Laboratory Animal Medicine (ULAM) and all 
procedures on live animals were performed in accordance with institutional guidelines 
and approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Michigan (PRO00007593; 5 May 2017). Euthanasia was performed with 
carbon dioxide, followed by removal of the heart. 
A total of 9 mice were divided into the following 3 groups of mice (n = 3 per group): (1) 
Diluent injected TRAMP mice (19 weeks, Strain 008215, Jackson Laboratory, Bar Harbor, 
ME, USA), (2) CFZ-HCl NP injected normal mice (19 weeks, C57BL/6, Jackson 
Laboratory, Bar Harbor, ME, USA), and (3) CFZ-HCl NP injected TRAMP mice (19 weeks, 
Strain 008215, Jackson Laboratory, Bar Harbor, ME, USA). The time indicated was the 
age of the mice at the point of euthanasia. For the diluent injected mice (Group 1), a total 
of 0.3 mL of diluent with 0 mg/mL CFZ-HCl NP was IV injected into each mouse. Briefly, 
the diluent for the IV injectable formulation was made using polysorbate 80 (0.5% w/v, 
59924 Sigma-Aldrich, St. Louis, MO, USA); sodium chloride (BP358, Fisher Scientific, 
Fair Lawn, NJ, USA) for isotonicity; and Milli-Q water. The pH was adjusted to pH 5 using 
0.01 M HCl or 0.01 M NaOH to ensure the stability of CFZ-HCl NPs in the formulation. 
The diluent was sterilized by sterile filtration with a syringe filter (09-719A; 0.22 µm, MCE, 
Sterile; Fisher Scientific, Fair Lawn, NJ, USA). The full details of the diluent formulation 




 For the CFZ-HCl NP injected mice (Groups 2 and 3), a total of 0.3 mL of 19 - 23 mg/mL 
CFZ-HCl NP was IV injected into each mouse, with the concentration of CFZ-HCl NP 
scaled according to the weight of the individual mice (a total CFZ-HCl NP dose of 200 
mg/kg). The full details of the CFZ-HCl NP formulation have been published previously 
69. This dose was selected as it represents an equivalent amount to 3-4 weeks of oral 
feeding performed in previous studies which allowed for sufficient accumulation of the 
drug in the organs 90. After 24 hours, the mice were sacrificed, and the prostates were 
harvested. Each prostate was separated into two halves: one half was snap frozen in 
liquid nitrogen for drug quantification, and the other half was embedded in Tissue-Plus 
Optimal Cutting Temperature (OCT) compound (4585, Fisher HealthCare, Houston, TX, 
USA) for histopathology. 
4.4.2 Quantification of CFZ-HCl NP in Tissues 
Quantification of CFZ-HCl NPs in tissues was performed using a previously published 
protocol with some modifications 90. Briefly, the harvested prostate was thawed, weighed, 
cut, and homogenized by sonication and mechanical homogenizer (Pro200; Pro 
Scientific, Oxford, CT) in Pierce® radioimmunoprecipitation assay (RIPA) buffer (89900; 
Thermo Scientific, Rockford, IL, USA). Homogenates were then filtered through Pierce® 
tissue strainers (87791; 250 µm, Thermo Scientific, Rockford, IL, USA) utilizing the gentle 
centrifugation (200 x g at 4°C for 5 min). The lipophilic tissue fraction was extracted with 
xylenes (CAS 1330-20-7/100-41-4; Fisher Chemical, Fair Lawn, NJ, USA) in triplicates, 
followed by the second extraction in triplicates with 9 M H2SO4 of diprotonated CFZ from 
the xylenes extract. Samples were centrifuged (2,000 x g at 4°C for 10 minutes) to 




volumes were recorded, and CFZ-HCl NP concentrations were determined 
spectrophotometrically. The absorbance of the supernatants was measured at λ = 540 
nm (A540) and 750 nm (A750) using a Synergy-2 plate reader (Biotek Instruments). 
Corrected absorbance (A540 - A750) was used to determine CFZ-HCl NP content via a 
standard curve of standards in 9 M H2SO4, and the concentration values were corrected 
for organ weight. To correct for extraction yield, known amounts of CFZ were added to 
the prostate sample before extractions; these samples were processed and analyzed 
concurrently with the test samples. For prostate tissues, the extraction yield averaged 
83%. 
4.4.3 Histopathology 
Histopathology was performed using a previously published protocol with some 
modifications 69. In brief, the frozen tissue blocks were sectioned (6 µm thick) using a 
Leica 3050S cryostat, and fixed in 4% paraformaldehyde (15710, Electron Microscopy 
Sciences, Hatfield, PA, USA) for 10 min. The samples were incubated with Hoechst 
33342 solution (H3570; 1 µM stock; 1:10,000 dilution in PBS; Life Technologies, 
Carlsbad, CA, USA) for 10 min at room temperature for nuclear detection. After staining 
was complete, sections were mounted with a drop of ProLong® Gold antifade reagent 
(P36930, Life Technologies, Carlsbad, CA, USA) and sealed with a cover slip. For the 
hematoxylin and eosin (HE) staining, the sectioning and staining were performed by the 
In-Vivo Animal Core of ULAM at the University of Michigan. Brightfield and fluorescence 





4.4.4 Brightfield and Fluorescence Microscopy 
Microscopy was performed using a Nikon Eclipse Ti inverted microscope (Nikon 
Instruments, Melville, NY, USA) as previously described 69,90,92. Briefly, brightfield images 
were captured using the Nikon DS-3 camera (Nikon Instruments, Melville, NY, USA), and 
fluorescence imaging in DAPI channel (350/405 nm, blue) and Cy5 channel (640/670 nm, 
far-red) was performed with the Photometrics CoolSnap MYO camera system 
(Photometrics, Tuscon, AZ, USA) under the control of Nikon NIS-Elements AR software 
(Nikon Instruments, Melville, NY, USA). Illumination for fluorescence imaging was 
provided by the X-Cite 120Q Widefield Fluorescence Microscope Excitation Light Source 
(Excelitas Technology, Waltham, MA, USA). 
4.4.5 Sensitivity of PA Imaging of CFZ-HCl NP 
The CFZ-HCl NPs were prepared for concentrations of 0, 0.001, 0.003, 0.01, 0.03, 0.1, 
0.3, and 1 mg/mL. Each concentration was mixed with whole blood to generate a total of 
10% blood by volume. 100 µL of each concentration was injected into a polyvinyl chloride 
tubing (Z280348, Sigma Aldrich, St. Louis, MO, USA). The portion of the tubing containing 
the CFZ-HCl NPs were submerged under water to allow for acoustic coupling with a 128-
element ultrasound probe with frequency range of 7 to 15 MHz (CL15-7, Philips, Andover, 
MA, USA). The ultrasound probe was placed parallel to the longitudinal section of the 
tube and connected to a commercially available research ultrasound platform (Vantage 
256, Verasonics, Redmond, WA, USA) for data acquisition. A tunable pulsed laser 
(Surelite OPO Plus, Continuum, Santa Clara, CA, USA) pumped by the third harmonic of 
an Nd:YAG laser (Surelite, Continuum, Santa Clara, CA, USA) was used to generate the 




a pulse duration of 5 ns, and a firing frequency of 10 Hz. The tube samples were imaged 
at a wavelength of 500 nm and averaged 20 times, with a total of 3 replicates performed. 
4.4.6 CFZ-HCl NP Imaging via PA Multiple Wavelength Unmixing 
The CFZ-HCl NPs were prepared for concentrations of 0, 0.003, 0.03, and 0.3 mg/mL, 
with the concentrations chosen based on the PA sensitivity results. An identical setup to 
the previous section was used with the exception that the tube samples were imaged at 
two wavelengths of 500 nm and 584 nm, and averaged 50 times. The wavelengths of 500 
nm and 584 nm were chosen as these are the known isosbestic points of oxyhemoglobin 
(HbO2) and deoxyhemoglobin (Hb), the two main chromophores in blood. The selection 
of the isosbestic points of blood prevented the need to distinguish between HbO2 and Hb, 
allowing for the analysis of the total hemoglobin (THb) concentration instead. If blood and 
CFZ-HCl NPs are assumed to be the main chromophores generating the PA signal, the 











]  (4.1) 
Here, k is a constant dependent on the light fluence, the Grüneisen parameter of the 
sample, and the sensitivity of the imaging system. It is assumed that the light fluence, and 
subsequently k, is wavelength independent after calibration of the laser output energy. 
PAλnm is the photoacoustic signal at λ nm, [THb] and [CFZ-HCl NP] are the concentrations 
of the total hemoglobin and CFZ-HCl NPs respectively, εTHb@λnm and εCFZ-HCL NP@λnm are 

















]  (4.2) 
With the optical extinction coefficients being known, and PAλnm being the PA signal 
measured, the right side of the matrix equation is completely known, allowing for the 
concentrations of [THb] and [CFZ-HCl NP] to be separately identified, albeit modified by 
the constant k. Hence, it should be noted that the concentrations measured are only 
relative concentrations, as an absolute concentration measurement would require a 
calibration measurement and the value of k to be identified, the latter of which is not a 
trivial task. 
4.4.7 Ex vivo PA Imaging of Prostate Samples 
The PA imaging setup is shown in Figure 4.1. The gelatin phantom was made using a 
concentration of 8 g/mL of gelatin from porcine skin (G2500, Sigma-Aldrich, St. Louis, 
MO, USA). The gelatin was poured into a mold to form a hollow cylindrical center and 
allowed to solidify. The prostate was placed in the center of the phantom, and 300 µL of 
PBS (pH 7.4) was added to submerge the prostate for acoustic coupling with the 
transducer. The gelatin phantom was placed on a calibrated rotating stage that allows for 
precise rotations of the gelatin phantom. The ultrasound transducer (CL15-7, Philips, 
Andover, MA, USA) was then placed perpendicular to the gelatin phantom at the height 
of the prostate sample. Ultrasound gel was added in between the transducer and the 
gelatin phantom for complete acoustic coupling. The ultrasound transducer was 




Verasonics, Redmond, WA, USA) for data acquisition. A tunable pulsed laser (Surelite 
OPO Plus, Continuum, Santa Clara, CA, USA) pumped by the third harmonic of an 
Nd:YAG laser (Surelite, Continuum, Santa Clara, CA, USA) was used to generate the PA 
signal. A top illumination approach was used as the prostate sample was thinner on its z-
axis, allowing for a more uniform laser energy distribution throughout the prostate sample. 
Fifty PA images were obtained at each angle, for two wavelengths of 500 nm and 584 
nm, respectively. This was repeated for 9 angles, for a total of 180o of rotation. The 50 
images were then averaged, and a simple back-projection reconstruction was performed 
to obtain the final image at each wavelength. The PA imaging system’s resolution is 
determined by the ultrasound transducer (CL15-7), with an approximately 226 μm lateral 
and 166 μm axial resolution at a depth of 6mm. However, due to the multiple angle 
imaging, the resolution is improved to the better of the two resolutions, at approximately 





Figure 4.1 PA imaging setup for ex vivo prostate imaging. Dashed box indicates placement location of the 
ultrasound transducer (CL15-7). 
The multiple wavelength unmixing algorithm previously specified was then performed to 
obtain the THb and CFZ-HCl NP relative concentrations. The CFZ-HCl NP signal was 
then normalized to the THb signal. This step was necessary as the prostate samples had 
different thicknesses and geometries, leading to different laser fluence distributions in the 
prostate samples depending on the imaging plane being measured. Mathematically, the 
constant “k” in matrix equations 4.1 and 4.2 is affected by this difference in laser fluences. 
However, by taking the ratio of CFZ-HCl NP/THb concentration, this constant is 
eliminated (with the assumption that k is wavelength-independent). This ensures that 
accurate comparisons can be made between prostate samples independent of their sizes. 




normalized CFZ-HCl NP signal with a corresponding THb signal below the background 
signal of the THb image was removed. Next, an upper threshold was applied to the 
normalized CFZ-HCl NP signal. These two steps were performed to remove any extreme 
normalized signals (i.e. very low THb signals results in extremely high normalized CFZ-
HCl NP signals). A lower threshold was also applied to the normalized CFZ-HCl NP signal 
to remove the background CFZ-HCl NP signal and enhance the dynamic range of the 
images. Finally, the image was then smoothed with a Gaussian filter. The thresholds and 
filters applied were identical for all images. 
4.4.8 Statistics 
All statistical analysis was performed using Matlab R2015b (MathWorks, Natick, MA, 
USA). Where relevant, the data are expressed as the mean +/- standard deviation. 
Significant differences were determined using two-tailed two sample t-tests (ttest2 
function) and a one-way analysis of variance (ANOVA) with Tukey's honest significant 
difference criterion (anova1 followed by multcompare function). 
4.5 Results  
4.5.1 CFZ-HCl NP Accumulation in Prostates 
To determine CFZ-HCl NP accumulation in the prostates, the mice were divided into 3 
groups. The first group consisted of TRAMP mice that were IV injected with the 
nanoparticle diluent to act as a negative control, and the second and third groups 
consisted of normal and TRAMP mice, respectively, that were IV injected with CFZ-HCl 
NPs. While CFZ is traditionally an orally fed drug, it requires several weeks of oral CFZ 




macrophages of various organs 90. However, as a diagnosis technique, a shorter time 
frame would make it a more promising method for diagnosis of prostate cancer. Thus, a 
biomimetic formulation of CFZ-HCl NPs, which has been previously determined to be 
suitable for IV administration 69, allowed us to achieve a high accumulation of CFZ-HCl 
NPs in the cancerous prostates within 24 hours post injection.  
HE stained sections of the TRAMP prostate (Figure 4.2A) showed that the mouse 
prostates were most likely in between the initial and advanced stages of adenocarcinoma, 
as the acinar lumens and interductal spaces were almost completely lost, even though 
the structure of each acinus remained intact 70. The normal prostate showed a normal 
physiology with a uniform layer of epithelial cells comprising the glands (Figure 4.2B). 
From a quantitative drug analysis of the prostates from CFZ-HCl NP injected animals, we 
observed that there was a much larger CFZ-HCl NP accumulation in the TRAMP 
prostates than in the normal prostates (Figure 4.2C), verified by histopathology and 
fluorescence images. Furthermore, we did not observe any CFZ-HCl NP accumulation in 
the prostates of diluent injected TRAMP mice (Figure 4.2D) or in the prostates of CFZ-
HCl NP injected normal mice (Figure 4.2E). However, there was clear accumulation of 
the CFZ-HCl NPs in the prostates of CFZ-HCl NP injected TRAMP (Figure 4.2F). These 
results supported the hypothesis that the IV injected CFZ-HCl NP has a greater 





Figure 4.2 Histopathology and CFZ-HCl NP quantification in prostates. HE stained sections of the prostate 
for (A) TRAMP mice, and (B) Normal mice at 19 weeks. (C) Quantified concentrations of CFZ-HCl NPs in 
the two CFZ-HCl NP injected groups. Co-registered fluorescence images of the prostate with a nuclear 
stain (DAPI) in blue and CFZ-HCl NPs (Cy5) in red for (D) diluent injected TRAMP mice, (E) CFZ-HCl NP 
injected normal mice, and (F) CFZ-HCl NP injected TRAMP mice. Scale bar = 50 µm. *** p-value < 0.001.   
4.5.2 Sensitivity of PA Imaging of CFZ-HCl NP 
After confirming that the CFZ-HCl NP accumulated at a higher concentration in the 
prostates of TRAMP mice, we identified if this increased accumulation could be detected 
via PA imaging. Since one of the main concerns for detecting the CFZ-HCl NP was its 
potential overlap in absorption spectra with blood, specifically with HbO2 and Hb (Figure 
4.3A), we first tested the minimum detectable concentration of CFZ-HCl NP in the 
presence of blood. Here, a concentration of 10% blood by volume was used to mimic 
physiological conditions 2. A wavelength of 500 nm was used because it was close to the 
peak absorption of CFZ-HCl NP, and it is also at a trough and isosbestic point of HbO2 
and Hb. By looking at the increase in PA signal amplitude at 500 nm with increasing CFZ-




of up to 3 µg/mL of CFZ-HCl NP (Figure 4.3B). Assuming that 1 g of the prostate organ 
has a volume of approximately 1 mL (with 1 g/mL being the density of water), CFZ-HCl 
NP was found to accumulate in the prostates of TRAMP mice with an average 
concentration of 60 µg/mL, as determined from the result in Figure 4.2C. This 
accumulation concentration is more than an order of magnitude above the detection 
threshold of 3 µg/mL. Hence, we concluded that the accumulation of CFZ-HCl NP in the 
prostates of TRAMP mice will be detectable via PA imaging.   
 
Figure 4.3 Absorption spectra and single-wavelength PA sensitivity of CFZ-HCl NP in the presence of 10% 
blood. (A) Overlaid absorption spectra of CFZ-HCl NP, HbO2, and Hb. (B) Normalized PA amplitude at 500 
nm for a sample with increasing [CFZ-HCl NP] in the presence of 10% blood on a logarithmic scale. Red 
dotted line indicates the minimum detection threshold based on the PA measurement on a sample of 10% 
blood in the absence of CFZ-HCl NP. Blue circle indicates the minimum detectable CFZ-HCL NP 
concentration of 3 µg/mL. (Inset) Normalized PA amplitude at 500 nm with increasing [CFZ-HCl NP] on a 
normal scale to show the approximate linearity between [CFZ-HCl NP] and the PA amplitude, at least up 




4.5.3 CFZ-HCl NP Imaging via PA Multiple Wavelength Unmixing 
Next, we verified if we would be able to distinguish the CFZ-HCl NP signal from the blood 
signal. To do this, we used the multiple wavelength unmixing method to decouple the 
CFZ-HCl NP signal from that of the blood. This method involves using multiple 
measurements at different laser wavelengths to isolate the contributions of each 
chromophore to the PA signal 16,46. In this study, only two wavelengths were used to 
identify the individual contributions of CFZ-HCl NP and total hemoglobin. Here, we 
observed that the CFZ-HCl NP signal could be distinguished from the THb signal (Figure 
4.4). This was demonstrated by the fact that we saw no change in the measured THb 
concentration after the deconvolution while the measured concentration of CFZ-HCl NP 
increased as expected. The blank solution (water) also showed very low THb and CFZ-
HCl NP signals. However, there was a difference in the background relative signal of THb 
and CFZ-HCl NP which was attributed to the fact that the tubing used to hold the samples 
generates a small PA signal on its own, leading to some small systematic errors in the 
measurement. Hence, we demonstrated that the multiple wavelength unmixing method 





Figure 4.4 Two-wavelength unmixing of CFZ-HCl NP from blood. A mixture of different concentrations of 
CFZ-HCl NP (shown on the y-axis) with 10% blood by volume in a tube was used. The two columns indicate 
the isolated contributions of THb and CFZ-HCl NP to the PA signal for each sample. Color bars only indicate 
the relative concentrations and not the actual concentrations. The last row shows the quantified relative 
concentrations for all the samples. “Blank” indicates a tube filled with water. 
4.5.4 Ex vivo PA Imaging of Prostate Samples 
After validating that decoupling the contributions of CFZ-HCl NP and blood could be 
achieved by multiple wavelength unmixing via the experiment on tube samples, we then 
performed ex vivo PA imaging of the mouse prostates. Here, we compared the same 3 
groups of mice shown in Figure 4.2. Figures 4.5A-C show the normalized CFZ-HCl NP 
signal over the blood signal for representative prostates in the 3 separate groups. The 
CFZ-HCl NP signal was normalized to the blood signal to help reduce any inaccuracies 
due to the difference in size of the prostates, as detailed in the methods. Figure 4.5D 




prostates in each of the 3 groups. We observed that there was a significantly higher CFZ-
HCl NP signal in the prostates of CFZ-HCl NP injected TRAMP mice compared to the 
other two groups, which matched the results shown in Figure 4.2. Furthermore, there was 
no significant difference between the diluent injected TRAMP prostates and the CFZ-HCl 
NP injected normal prostates. Thus, we demonstrated that PA imaging can be used to 
detect the differences in accumulation of CFZ-HCL NPs in the prostates in an ex vivo 
setting. 
 
Figure 4.5. Ex vivo PA imaging results. CFZ-HCl NP signal normalized to the THb signal for prostates of 
(A) diluent injected TRAMP mice (DIL-TMP), (B) CFZ-HCl NP injected normal mice (CFZ-NOR), and (C) 
CFZ-HCl NP injected TRAMP mice (CFZ-TMP). Color bars indicates the CFZ-HCl NP signal normalized to 
the THb signal as determined by the two-wavelength unmixing. (D) Mean normalized CFZ-HCl NP signal 
for each group within the organ boundaries as delineated by the US image (shown in the representative 
images as a white dotted line). * p-value < 0.05, ** p-value < 0.01. 
4.6 Discussion 
While the multiple wavelength unmixing technique helps to mitigate the interference of 
endogenous chromophores, it is not a perfect technique, and there will always be 
background noise from chromophores that are not accounted for in the algorithm. For 
example, the imaging results in Figure 4.5 showed a strong background signal for CFZ-
HCl NP in the absence or low concentration of the drug. In addition, there appeared to be 
a slightly higher CFZ-HCl NP signal in the DIL-TMP group compared to the CFZ-NOR 




samples used in Figure 4.4, other chromophores such as myoglobin (and its many 
different forms) could also be present in the prostate, contributing to some inaccuracies 
in the CFZ-HCl NP signal. If these chromophores could be identified and accounted for, 
with more PA measurements made at additional wavelengths, the sensitivity of the PA 
imaging technique towards CFZ-HCl NP could be improved. In addition, the fluence 
distribution in the prostate tissues is assumed to be wavelength-independent, which is 
typically a good assumption for near-surface PA imaging, less so with increasing imaging 
depth 16,25. Addressing these two limitations in the current approach would improve the 
sensitivity of PA imaging towards the detection of CFZ-HCl NP, allowing for even more 
precise and accurate detection. The ability to detect and distinguish smaller 
concentrations of CFZ-HCl NP will allow for many new possibilities using this technique, 
such as the study of prostate cancer progression in its early stages, where CFZ-HCl NP 
accumulation in the prostate is expected to be small. Additionally, there are concerns that 
normalization of the CFZ-HCl NP to the THb signal would reduce the sensitivity of PA 
imaging to detect CFZ-HCl NPs due to increasing vasculature in the prostate tumor with 
cancer progression. While this may be true, we believe that the difference in accumulation 
of CFZ-HCl NPs between cancerous and non-cancerous prostates (as shown in Figure 
4.2C) will far outweigh any variations in tumor vasculature. 
It should also be noted that there are other PA contrast agents that can be used in the 
near-infrared spectrum range (e.g. indocyanine-green and gold nanorods) 14,15, which 
would lead to less endogenous chromophore interference. However, none of them come 
with the intrinsic benefit of CFZ-HCl NP, which specifically accumulates in tissue 




in most forms of cancer, this drug could potentially be used in the diagnosis of other forms 
of cancer as well. Furthermore, most of the other contrast agents are not clinically 
approved and are still limited to the research field 14. CFZ, on the other hand, is an FDA-
approved drug with minimal harmful side-effects 90, which makes it more likely to be 
translated for clinical use. Therefore, we expect the benefits of using CFZ-HCl NP as a 
diagnostic contrast agent to outweigh the higher signal interference with endogenous 
chromophores compared to other known contrast agents. 
Besides the limitations mentioned above, there are also other challenges for translating 
this into a practical probe for in vivo monitoring of prostate cancer development and 
staging, such as the imaging depth needed for imaging prostates in vivo due to the 
prostate’s anatomical location both in animals and humans. Due to the CFZ-HCl NPs low 
absorption wavelength, deep imaging depths with the nanoparticle may be limited. 
However, there is ongoing research in this field, where potential solutions to this include 
the development of a minimally invasive needle-based PA imaging system that can be 
inserted close to the prostate 68,93-95. This helps to bring both the light source and 
ultrasound transducer close to the prostate, significantly reducing the absorption of the 
light signal from other chromophores as well as the attenuation of the ultrasound signal 
in the body.  
In conclusion, we have shown that IV injected CFZ-HCl NP accumulates at a higher 
concentration in cancerous prostates than in normal prostates within 24 hours post 
injection in a TRAMP mouse model. In the presence of blood, one of the main 
endogenous chromophores in the body, we were able to isolate the signal of CFZ-HCl 




technique in PA imaging to detect the higher accumulation of CFZ-HCl NP in the 
cancerous prostates compared to the normal prostates. Hence, we believe that 
differences in the interaction of CFZ-HCl NP with normal vs cancerous prostates, together 
with PA imaging, could lead to the development of a noninvasive technique for the 
detection and monitoring of prostate tumor induction and progression in an animal model 
of the disease, while providing useful information to facilitate the design of next generation 
imaging probes for the development of noninvasive diagnosis and staging of prostate 








In Vivo Photoacoustic Potassium Imaging of the Tumor 
Microenvironment 
5.1 Brief Foreword 
This chapter focuses on the photoacoustic chemical imaging method for potassium 
imaging in in vivo small animal models. At the time of writing, the work shown here is 
currently being submitted for publication in a peer-reviewed journal. 
5.2 Abstract  
The accumulation of potassium (K+) in the tumor microenvironment (TME) has been 
recently shown to inhibit immune cell efficacy, and thus immunotherapy. Despite the 
abundance of K+ in the body, few ways exist to measure it in vivo. To address this 
technology gap, we combine an optical K+ nanosensor with photoacoustic (PA) imaging. 
The nanosensor is based on a solvatochromic dye whose absorption spectrum shifts as 
a function of K+ concentration. Using multi-wavelength deconvolution, we are able to 
separate this nanosensor’s signals from those of the background chromophores, allowing 
for quantitative evaluation of K+ concentration. We imaged K+ concentrations in healthy 
muscle vs. tumor tissue in a mouse model. Significantly elevated K+ levels were found in 




found in muscle. These PA measurements were confirmed by extraction of the tumor 
interstitial fluid and subsequent measurement via mass spectrometry.  
5.3 Introduction 
Potassium (K+) is the most abundant cation in the body 96. The evolution of live cells 
started by keeping Na+ out of and K+ inside the cell 97,98. Steep gradients exist in its 
distribution as intracellular K+ concentrations are typically greater than 100 mM 96,99, while 
extracellular K+ concentrations are approximately 5 mM 96, It has long been known that 
the tumor microenvironment (TME) can have suppressive effects on T cells 100. However, 
this suppression was only recently attributed to disruptions in the K+ concentration 101. 
Notably, necrotic cell death in the nutrient-starved core of tumors leads to the release of 
vast quantities of intracellular K+. The release of this K+ induces local hyperkalemia in the 
TME with a reported 5-10 fold increase in K+ concentration 101. In two seminal studies, Eil 
and colleagues determined that elevated K+ suppresses T cell effector function and 
prevents immune cells from maturing 101,102. 
Despite the importance of K+ in the body, there exist only a few ways to measure K+ 
concentrations in vivo. Magnetic resonance imaging (MRI) has been used in the past to 
measure in vivo K+ concentrations 103-105. However, the 39K MRI imaging is an expensive 
technique, and is limited by availability and especially by poor resolution (voxel size of ~1 
mL) 103. Few commercially available potassium-sensitive dyes exist (PBFI, asante-green 
series), and of these none are excitable in either the near- or far-infrared. Visible 
wavelength dyes for fluorescence imaging are ill-suited for in vivo experiments due to the 
severe scattering of light in biological tissue. Miniaturized electrodes, the gold standard 




and temporal ion distribution images. It is of note that, in the previously mentioned 
immunological studies, K+ was measured by centrifuging ex vivo tumors to collect tumor 
interstitial fluid 101,106, which was then measured via electrode, thus losing any 
spatiotemporal resolution. 
To generate structural images that contain the chemical information in biological samples, 
we recently developed photoacoustic chemical imaging (PACI). PACI benefits on one 
hand from the good sensitivity of the optical detection techniques and on the other hand 
from the lower tissue scattering and thus excellent penetration and spatial resolution of 
ultrasound imaging 107,108. PACI utilizes exogenous contrast agents, typically 
nanosensors, whose optical absorption properties change in response to some analyte 
of interest. The advantages of PACI have already allowed the monitoring of lithium 
treatments for bipolar disorder 18, measuring of tissue oxygenation using a lifetime-based 
approach 17,19-22, and measuring of tumor pH 16. 
In this study, we extend PACI through the use of an ionophore-based optical K+ 
nanosensor. While we have previously developed a K+ sensor for PACI, it had a cross-
sensitivity with pH due to its reliance on a pH dye as part of its sensing mechanism 41. 
Hence, its accuracy would be affected by the acidic tumor microenvironment. As such, 
we adopted a pH-insensitive K+ sensor for in vivo PACI measurements of K+. Invented by 
Eric Bakker’s group, this optode formulation utilizes positively charged, solvatochromic 
dyes which are pushed from the hydrophobic interior of the nanoparticle to its hydrophilic 
surface 109. The transition between the interior and exterior of the nanoparticle forces a 
change in the dye’s optical absorption spectrum which can be measured by PA imaging. 




subcutaneous tumors in mice, where its signal is deconvoluted from that of blood. This 
method could be extended to measuring other ions, such as Na+ and Cl- 110-112. 
Specifically, here we demonstrate its utility by documenting in vivo the high overall 
concentration of K+ in tumor tissue compared to that in healthy muscle, and quantitatively 
verifying PACI results using mass spectroscopy measurements on the interstitial fluid 
harvested from each tumor.  
5.4 Methods 
5.4.1 Materials 
Millipore water was used for all syntheses and buffer preparations. Chemicals purchased 
from Sigma-Aldrich (St. Louis, Mississippi, USA) include Pluronic F-127, valinomycin, 
dioctyl sebacate, sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate, potassium 
chloride, sodium chloride, calcium chloride dihydrate, magnesium chloride, 3-(N-
morpholino)propanesulfonic acid, acetonitrile, acetic anhydride, 1-iodooctadecane, 2-
methylbenzothiazole, (dimethylamino)cinnamaldehyde, sodium iodide, and methanol.  
5.4.2 SD2 Synthesis 
Synthesis of SD2 was first reported by Eric Bakker’s group, and few changes were made 
to the original protocol 109. Briefly, 1.5 g 2-methylbenzothiazole and 3.8 g 1-
iodooctadecane were dissolved and refluxed in acetonitrile for 24 hours. The solution was 
removed from heat and allowed to solidify. The crude product was precipitated in diethyl 
ether, collected, and washed several times in diethyl ether. 265 mg of this product, along 
with 122 mg (dimethylamino)cinnamaldehyde, was then dissolved in acetic anhydride and 




mM sodium iodide (in Millipore water). The dark purple precipitate was washed several 
times with water, dried, and collected. 
5.4.3 Nanoparticle Synthesis 
The protocol for the synthesis of the SDKNP was developed by Eric Bakker’s group.109 
To generate a concentrated solution of nanoparticles, the following protocol was used. 
0.2 mg SD2 (synthesized in house, see above), 0.9 mg sodium tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate, 1.2 mg valinomycin, 5 mg Pluronic F-127, and 8.75 L 
(8 mg) dioctyl sebacate were dissolved in 3 mL of methanol. The methanol cocktail was 
then injected into 30 mL of Millipore water under vigorous stirring. The surface of the 
methanol-water mixture was blasted with nitrogen gas for 1 hour to remove the methanol. 
The nanoparticle solution was concentrated to the desired concentration using an Amicon 
Ultra-15 centrifuge filter (100k Da).  
5.4.4 Mass Spectrometry – Solvatochromic Dye Characterization 
Electrospray ionization mass spectrometry was performed by the University of Michigan’s 
Mass Spectrometry Core. 
5.4.5 DLS and Zeta-Potential 
Dynamic Light Scattering and Zeta-Potential measurements were performed at a 
nanosensor concentration of 1 mg/mL using a Beckman Coulter analyzer. 
5.4.6 MTT 
HeLa cells (ATCC authenticated) were cultured in Dulbecco’s Modified Eagle Media with 




24 well plate and allowed to grow over night in 1 mL of growth media. SDKNPs were 
incubated for various times at a concentration of 1 mg/mL. Following incubation, 500 L 
of incubation media was replaced with 500 L of MTT solution (5 mg/mL in PBS) and 
incubated for 4 hours. Once finished, all media was removed from the wells and replaced 
with 1 mL of DMSO. This solution was then incubated for 1 hour at which point the solution 
was removed and its absorption spectrum measured in a UV-Vis spectrophotometer. 
Absorption peaks at 590 nm were compared, and all samples were repeated 4 times. 
 
Figure 5.1 General PA setup for in vitro and in vivo imaging. For acoustic coupling, in vitro tube experiments 
were conducted in water, while in vivo mice experiments were conducted using ultrasound gel. A partial 
reflector (glass slide) was used to reflect part (<20%) of the laser beam energy to the power meter for 
energy monitoring. The PA signal was acquired using an ultrasound transducer (CL15-7) connected to a 
research ultrasound acquisition system (Vantage 256, Verasonics, Kirkland, WA, USA). 
5.4.7 PA and UV Calibration 
For the UV calibration, K+ calibration samples of 0, 1, 5, 10, 20, 30, 50, 70, 100, and 150 
mM K+ with 1 mg/mL of SDKNP were prepared. Samples were prepared in pH 7.4 MOPS-
buffered saline solution containing physiologically relevant concentrations of interfering 
cations: sodium (150mM), magnesium (1mM), and calcium (2.6mM). The absorption 




1600 UV-Vis Spectrophotometer (Shimadzu, Kyoto, Kyoto, Japan). For the PA 
calibration, K+ calibration samples of 0, 1, 5, 10, 20, 30, 40, 50, 70, 100, and 150 mM K+ 
with 10 mg/mL of SDKNP were prepared. 75 µL of each sample was added into a 
transparent PVC tubing. The tube samples were submerged in water for acoustic 
coupling. The tube samples were then imaged using a PACI system consisting of a 
tunable pulsed laser (Continuum, Santa Clara, CA, USA) and a 128-element ultrasound 
probe with frequency range of 7 to 15 MHz (CL15-7, Philips, Andover, MA, USA). The 
tunable pulsed laser pumped by the third harmonic of an Nd:YAG laser (Continuum, 
Santa Clara, CA, USA), has a pulse duration of 5 ns, a firing frequency of 10 Hz, and is 
capable of achieving wavelength tuning in the range of 410-680 nm and 710-2500 nm. 
The ultrasound probe was then connected to a commercially available research 
ultrasound platform (Vantage 256, Verasonics, Kirkland, WA, USA) for data acquisition. 
The general PA imaging setup is shown in Figure 5.1. The PA signal was obtained for 6 
wavelengths of 545, 560, 576, 584, 605, and 625 nm, chosen based on the absorption 
spectra obtained. Each PA signal was averaged 20 times, with a total of 4 replicates 
performed for each sample. A simple light fluence correction was performed where the 
PA signal was normalized to the average energy measured for each wavelength using a 
power meter (Newport, Irvine, CA, USA). 
5.4.8 PA Multi-Wavelength Unmixing 
An identical setup to the PA calibration experiment was performed. K+ samples of 2, 5, 
20, 40, 50, and 150 mM were prepared in the presence of 1% blood v/v and 10 mg/mL of 
SDKNP as well as a blank sample which only contained saline solution. PA imaging was 




were chosen based on the isosbestic points and maximal difference in the extinction 
coefficients of SDKNP and hemoglobin. Multi-wavelength unmixing was performed 
according to the following steps. Firstly, at each wavelength, the PA signal can be 
modelled as shown in Eq. 5.1. 
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where λ is the wavelength in nm, [SDKNP] is the SDKNP concentration, [HbO2] is the 
oxyhemoglobin concentration, [Hb] is the deoxyhemoglobin concentration, ε is the 
extinction coefficient, and k is a constant associated with multiple parameters such as 
light fluence, the Grüneisen parameter of the sample, and the sensitivity of the imaging 
system. It should be noted that εSDKNP is dependent on both λ and the K+ concentration. 
The extinction coefficients of Hb and HbO2 for each λ are known values, while the 
extinction coefficient of SDKNP can be measured at each λ and for a range of K+ values. 
Here, we measured the value of εSDKNP for K+ values of 0, 1, 5, 10, 20, 30, 40, 50, 60, 70, 
80, 90, 100, 125, 150, and 200 mM using a UV-VIS spectrophotometer. This left only 4 
unknowns in the above equation, specifically [SDKNP], [HbO2], [Hb], and [K+]. Using 
simple linear algebra, the 4 unknowns can be solved by making at least 4 separate 
measurements at different wavelengths. Here, we used 6 wavelengths to solve the linear 
equations for increased accuracy, as it is widely known that additional measurements can 
help to improve the accuracy of the unmixed results 23,27,28. A notable limitation to this 
technique is that the estimation of the [K+] is based on measurements of the extinction 
coefficient of the SDKNP at discrete K+ values, meaning that the values of the measured 




εSDKNP response to K+ by using an equation-based approach. This approach, while 
allowing for continuous K+ estimates, has its own drawbacks in that no simple equation 
model can perfectly capture the εSDKNP response to K+, meaning that approximations will 
have to be made, reducing the accuracy of the measurements. 
5.4.9 In Vivo PACI of K+  
Animal care was provided by the Unit for Laboratory Animal Medicine (ULAM), and all 
procedures on live animals were performed in accordance with institutional guidelines 
and approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Michigan. A total of 6 mice were used in the in vivo imaging experiment. To 
generate the subcutaneous tumors, approximately 1x106 9L glioma cells (ATCC, 
Manassas, VA, USA) in 0.1 mL of RPMI 1640 (Gibco, Waltham, MA, USA) was 
subcutaneously injected into the right flank of 5-week old nude mice (Envigo, Huntingdon, 
Cambridgeshire, UK). The tumors were allowed to grow till a size of approximately 1 cm 
in diameter. 0.05 mL of 10 mg/mL SDKNP was then locally injected into the tumor, 
followed by PA imaging immediately after the injection. This was repeated with the thigh 
muscle on the opposite flank, where 0.05 mL of 10 mg/mL SDKNP was locally injected in 
the thigh muscle, followed by PA imaging immediately after the injection. All PA imaging 
was conducted for the same 6 wavelengths of 545, 560, 576, 584, 605, and 625 nm, with 
a total of 80 averages per image. A simple light fluence correction was performed where 
the PA signal was normalized to the average energy measured for each wavelength using 
the power meter. Multi-wavelength unmixing was conducted according to the same 
protocol as previously mentioned with the exception that only K+ values between 0-125 




extracellular tumor K+. After the imaging, the mice were euthanized, and the tumor 
harvested. An adaptation of the protocol performed by Eil et al. was conducted to collect 
the extracellular fluid from the tumor. Briefly, the tumor was first flushed with saline to 
remove surface blood and blotted gently with Kimwipe (Kimberly-Clark, Irving, TX, USA) 
to dry. The tumor then was placed in a SpinX centrifuge tube filter (Corning, New York, 
NY, USA) and centrifuged at increasing speeds of 1000, 2000, 4000, and 8000 RPM for 
10 minutes each 106. Approximately 4-10 µL of extracellular fluid was collected per tumor. 
The extracellular fluid was then sent for inductively coupled plasma mass spectroscopy. 
5.4.10 Inductively Coupled Plasma Mass Spectroscopy 
Tumor interstitial fluid was diluted with Millipore water by a factor of 5000 prior to 
measurement with a Perkin-Elmer Nexion 2000 ICP-MS (Perkin-Elmer, Waltham, MA, 
USA). The machine was calibrated using standards prepared at 50, 100, 250, 500, and 
750 PPB K+ using potassium chloride as a source for K+ ions.  
5.4.11 Statistical Analysis 
All statistical analysis was performed using Matlab 2016a (MathWorks, Natick, MA, USA). 
Where relevant, the data are expressed as the mean +/- standard deviation. Significant 
differences were determined using two-tailed two sample t-tests (ttest2 function). 
5.5 Results 
To test the capabilities of the SDKNP for PACI of K+, we first compared the response of 
the SDKNP to K+ using both PACI and UV-Vis spectrophotometry. Figure 5.2a shows the 
absorption spectra obtained for SDKNP at various K+ levels. The largest absorption 




trend at around 545 nm. The isosbestic point of the SDKNP is at approximately 560 nm. 
Making use of these wavelength ranges, the PA and UV-Vis calibration ratios were plotted 
in Figures 5.2b-f. These calibration ratios show the changes in the PA and the UV-Vis 
signals with respect to the isosbestic point for increasing concentrations of K+. As the PA 
signal of a molecule is directly proportional to its absorption, the PA calibration is expected 
to match that of the UV-Vis calibration.  To show the good agreement between the PA 
and UV-Vis measurements, the ratios are co-plotted in Figures 5.2b-f to show the 
similarity between the ratios measured by both modalities. These ratios generally showed 
a signal decrease with increasing K+ concentration, with exception of the 545nm/560nm 
ratio. The SDKNP is most sensitive between 0-50 mM K+, an ideal range for the expected 
in vivo tumor K+ concentration. Based on these results, we used the UV-Vis 
spectrophotometer measurements for later calibrations, as they generally provided 





Figure 5.2 Absorption spectra and PA K+ calibrations compared to UV-Vis K+ calibrations. (a) Absorption 
spectra of SDKNP for various K+ concentrations, oxyhemoglobin (HbO2), and deoxyhemoglobin (Hb). PA 
and UV-Vis ratio measurements for (b) 625nm/560nm, (c) 605nm/560nm, (d) 584nm/560nm, (e) 
576nm/560nm, and (f) 545nm/560nm. There is excellent agreement between the PA and UV-Vis 
calibrations. 
Next, we analyzed the capability of separating the SDKNP signal from the expected in 
vivo endogenous chromophores of deoxyhemoglobin (Hb) and oxyhemoglobin (HbO2). 
While other chromophores such as melanin and water are also present in biological 
tissue, Hb and HbO2 are expected to be the major PA signal contributors within the 545-
625 nm wavelength range in the tumor. Using a similar setup as the calibration 
experiment, multi-wavelength unmixing was performed for various K+ samples in the 
presence of 1% blood v/v. This volume of blood was used as it is close to the estimated 
blood volume fraction in a tumor tissue (for breast cancer) 2. Using a 6-wavelength 
unmixing technique, the concentrations of K+, SDKNP, Hb, and HbO2 were identified with 




as the oxygenation of the sample was not controlled and the total hemoglobin (THb) 
concentration was expected to serve as a more precise measurement. Within the 
SDKNP’s sensitivity range of 0-50 mM, the unmixed measurements of K+ concentration 
showed good accuracy levels (+/- 5 mM), with exception of the 20 mM sample. Outside 
this range, the measurement accuracy drops rapidly, although qualitative increases can 
be observed, as is shown by the significantly lower PACI estimate of 76 mM for the 150 
mM K+ sample. There is also some noticeable bleed through of the SDKNP and blood 
signals at higher K+ concentrations. This is most likely due to the absorption spectra of 
the SDKNP being more similar to blood at higher K+ concentrations, especially that of 
deoxyhemoglobin (Figure 5.2a). It should be noted that this does not affect the K+ 
measurement significantly, as most of the error is localized in the [SDKNP] and [THb] 






Figure 5.3 PA multi-wavelength unmixing for SDKNP samples in a tube for determining total hemoglobin 
concentration ([THb]), SDKNP concentration ([SDKNP]), and K+ concentration ([K+]). All samples contain 
SDKNP and 1% blood v/v at the specified K+ concentrations, with exception of “Blank”, which only contains 
saline solution. Sample values of K+ are provided at the top of the figure, while the measured values 
obtained via deconvolution are given at the bottom of the figure. Measured values pertain to the average 
K+ in the region of interest outlined by the white box. 
After verifying the ability to measure the K+ signal in vitro in the presence of blood, we 
then tested the ability to perform in vivo measurement of K+ in a subcutaneous tumor 
mouse model. We locally injected 0.05 mL of 10 mg/mL SDKNP into the tumor and the 
thigh muscle of the mice before conducting PACI at the 6 wavelengths. Figure 5.4a shows 
an example of the map of oxygen saturation, SDKNP concentration, and K+ concentration 
in the tumor and the muscle as measured by PA multi-wavelength unmixing for an 
individual mouse. Figure 5.4b shows the average hemoglobin oxygen saturation across 
all mice (n=6). While there is a slight decrease in the average tumor hemoglobin oxygen 
saturation compared to the muscle (47.5% compared to 52.3%), it was not statistically 
significant in this study. Figure 5.4c shows the average SDKNP concentration across all 
mice, where there was no significant difference detected between the tumor and the 
muscle (0.024 vs 0.024 A.U.). As equal concentrations of SDKNP were injected into the 
tumor and the muscle, this result was expected. Figure 5.4d shows the average K+ 
concentration between the tumor and the muscle, where the tumor K+ was significantly 
higher than the muscle K+. We observe an average K+ concentration of 29 mM (range of 
22-49 mM) in the TME, as expected from the predicted 5-10 fold increase report by Eil et 
al 101. In the muscle samples, we see an average concentration of 19 mM (range of 14-





Figure 5.4 In vivo PA imaging with overlaid ultrasound images of subcutaneous tumors and thigh muscles 
(control) in nude mice. (a) Multi-wavelength unmixing performed to identify the hemoglobin oxygenation 
saturation (%SO2), SDKNP concentration ([SDKNP]), and K+ concentration ([K+]). The average value 
across all mice (n=6) in the tumor and the muscle for (b) %SO2, (c) [SDKNP], and (d) [K+], as determined 
by multi-wavelength unmixing. ‘N.S.’ indicates no significance, ‘*’ indicates p < 0.05. 
To validate the accuracy of the K+ measurements in vivo, we then measured the average 
K+ within the tumor via a method involving centrifugation to extract the interstitial fluid of 
the tumor, followed by inductively coupled plasma mass spectroscopy (ICP-MS) to 
measure the K+ concentration of the extracted fluid. The centrifugation method was used 
by Eil et al. to measure the K+ concentration of the tumor 101. The results of the ICP 
measurements are compared to the PACI measurements in Figure 5.5. Figure 5.5a 
shows the average K+ concentration measured by PACI vs ICP for each of the individual 
mouse tumors. Figure 5.5b shows a box plot of the distribution of average K+ 
measurements for PA imaging and ICP.  Here, the mean value of K+ measured using 




48 mM). Figure 5.5c shows the correlation between the average K+ measurements made 
by PACI as compared to the ICP measurements. Generally, there was good agreement 
between the two K+ measurements, with a correlation value of r2=0.70. 
 
Figure 5.5 Average K+ measurement in the tumor from PA imaging vs ICP. Average K+ in the tumor for (a) 
individual mouse measurements, and (b) across all mouse samples (n=6). ‘N.S.’ indicates no significance. 
(c) Correlation analysis between the ICP and the PACI measurements. 
To further analyze the capability of our PACI technology for detecting spatial information 
within the tumor, we analyzed the K+ distribution within the tumor core and the periphery. 
As it has been reported that the necrotic core was the cause of the elevated K+ in the 
tumor, we wanted to identify if there was a difference in the K+ concentration within the 
tumor core (where the necrotic cores are expected), as compared to the peripheral 
regions of the tumor. Based on this, we would expect to see a higher K+ concentration in 
the tumor core as opposed to the periphery. The results of our analysis are shown in 
Figure 5.6, where an example of the determined regions of interest are shown in Figure 
5.6a. The cores were demarcated by taking a region of approximately 40% of the entire 
demarcated tumor, centered around the estimated geometric center of the tumor. Here, 
we noted that there was an increase in the measured K+ concentration in the tumor core 




higher). These observations suggest that elevated K+ within tumors may not be uniform, 
and that this spatial difference can potentially be detected via PACI. 
 
 
Figure 5.6 Further analysis of the measured K+ within the tumor core vs the tumor periphery. (a) An overlaid 
PA and ultrasound image showing the regions of interest of the core and the periphery, outlined in red. (b) 
Measured K+ concentrations for each mouse for the tumor core and the tumor periphery.  
5.6 Discussion 
In this study, we demonstrate the ability of PACI to measure the K+ concentration in a 
tumor in vivo, and show the elevated K+ concentration in the tumor compared to the 
muscle tissue. These results were verified using ICP-MS with good correlation between 
the two independent measurement techniques (r2=0.70). While Eil et al. have 
demonstrated that TME hyperkalemia induces elevated intracellular K+, it remains 
unknown at what K+ threshold this suppressive effect manifests itself. The ability to 
measure K+ concentrations in vivo could provide an essential tool to the field of 
immunology, with studies no longer having to rely on in vitro measurements of K+ at single 
time points with no spatial resolution. Additionally, an example of the spatial distribution 
of the TME hyperkalemia, as measured by our PACI technique, have been provided here. 




different time point of the tumor’s development, especially at long times and large tumors. 
PACI of K+ is ideally suited for characterizing these physiological phenomena, allowing 
for quantitative and spatial measurements of K+ in an in vivo mouse tumor, and potentially 
in a patient’s tumor.  
There are still improvements that can be made with the K+ measurement. Regarding the 
discrepancies seen in Figure 5.3, besides instrument calibration errors (UV-Vis 
spectrophotometer, ICP-MS), the PACI errors are mainly attributed to inaccuracies in the 
multi-wavelength unmixing technique, due to the wavelength-dependent light fluence 
attenuation in the sample, namely the “rainbow effect”, and the wavelength-dependent 
laser energy output. While the latter is mostly corrected for by monitoring the laser energy 
through the partial reflector in the setup, the former is significantly more challenging to 
correct. A significant amount of research has been dedicated to this area, where methods 
to model the light fluence distribution in a tissue sample are being studied 25,26,113. Without 
this wavelength-dependent light fluence correction, quantitative PA imaging is usually 
limited to surface/subcutaneous tumors. In a previous study, we have shown good 
accuracy within 6 mm depth from the tumor surface 16. Besides light fluence modelling, 
increasing the number of wavelengths used in the imaging and multi-wavelength 
unmixing can also improve the accuracy of the measurements 23,27,28. The latter method, 
however, has its own drawbacks in that the imaging time will be significantly increased, 
depending on the number of wavelengths desired. 
Additionally, there are some concerns regarding the toxicity of the current formulation of 
the SDKNP. While not having significant toxicity within 2 hours, prolonged exposure does 




largely attributable to the use of valinomycin as the K+ ionophore. The toxicity of the 
SDKNP is the reason behind the use of a local injection rather than a targeted intravenous 
injection approach in this study. However, there are adjustments that can be made to the 
nanoparticle matrix to allow for substitution with a less toxic ionophore, such as BME-44. 
Notably, the Pluronic polymer is highly biocompatible and in wide medical use 114. That 
being said, the strength of using these ionophore-based optical sensors is the relative 
ease at which sensors for other materials can be developed. For example, substituting 
valinomycin for a sodium ionophore allows for the development of a PA sodium sensor 
with relative ease. Additional substitution of ionophores and plasticizers would allow for 
sensing multivalent cations, such as magnesium, calcium, or transition metal ions, though 
non-trivial adjustments would be required, especially as the physiological concentrations 
of these species are much lower than that of K+. 
5.7 Conclusion 
Despite its ubiquitous and abundant presence in the body, our ability to analyze K+ 
concentration in vivo remains largely limited to the one-dimensional results gathered from 
electrodes. Here, we extended our previous work on PACI of tissue oxygenation and pH 
to include K+. The effort utilized an exogenous contrast agent whose change in optical 
absorption spectrum allows for PA probing of the K+ concentration. Our technique was 
verified in vitro and then implemented in vivo for measuring the concentration and 
characterizing the spatial distribution of K+ within the TME. We compared the here 
described PACI measurement results to those initially used to describe tumor 
hyperkalemia and found good agreement between them. In summary, this work 





5.8.1 Solvatochromic Dye Characterization 
The solvatochromic dye utilized by the nanosensor is synthesized in house using a 
protocol developed by Eric Bakker’s group 109. We report here the mass spectrum of the 
final product (Bakker: 559.5, Kopelman: 559.4). 
 
Figure 5.7 Mass spectrum of the synthesized and purified dye using the protocol described in the methods 
section. Measurements were made using positive ion electronspray mass spectrometry and performed by 
the University of Michigan’s mass spectrometry core. The reported mass of the dye was 559.5Da; we 
measured a mass of 559.4Da. 
5.8.2 Solvatochromic Dye, Potassium-sensing Nanoparticle (SDKNP) 
Characterization 
SDKNP size was evaluated using both Dynamic Light Scattering (Figure 8) and 
Transmission Electron Microscopy (Figure 9). DLS measurements are seen in Figure 8, 
where we observed an average nanosensor diameter of 90nm with a polydispersity index 
(PDI) of 0.107. Zeta potential () measurements indicated that the SDKNP is highly stable, 





Figure 5.8 Dynamic Light Scattering measurements of SDKNP diameter. The average nanosensor size is 
90nm, with a PDI of 0.107. 
TEM measurements of nanoparticle diameter yielded an average diameter of 45nm. DLS 
values are often larger than those measured by TEM, and the discrepancies are attributed 





























Figure 5.9 TEM images of the SDKNP taken at 5mg/mL in water. An average diameter of approximately 
50nm is observed. 
5.8.3 SDKNP Toxicity 
An MTT assay, using SDKNP at 1 mg/mL, found that the toxicity of the nanosensor 
increased overtime, though little toxicity was observed in the first two hours (Figure 10). 
The increase in toxicity is likely attributable to degradation of the micelle and subsequent 
release of valinomycin, whose toxic properties are well known. 
 
Figure 5.10 Results of an MTT assay evaluating the toxicity of the SDKNP. We observe limited toxicity 
over the first two hours of incubation, but prolonged exposure results in significant cell death. Error bars 




























Conclusion and Future Work 
The work in this thesis has demonstrated some of the applications of nanoparticle-
enabled PA imaging especially in the field of in vivo cancer imaging. While certainly broad 
in their potential applications, the work in this thesis has focused on the role of 
nanoparticles for contrast enhancement and molecular imaging in in vivo cancer models 
using PA imaging. 
Chapter 3 demonstrated an application for PA contrast enhancement using 
phosphorescence capable contrast agents that relies on the transient triplet differential 
signal from these contrast agents. Here, the potential use of the TTD technology was 
demonstrated for contrast enhancement in cancer detection. In addition, the study also 
briefly mentions the current use of this technology in oxygenation measurements in vivo. 
However, this technology is not limited to use as a tool in these two areas but has potential 
widespread uses in any application that uses these contrast agents. For example, 
methylene blue (the contrast agent used in this study), is a commonly used contrast agent 
in sentinel lymph node detection 115,116, and as a photosensitizing agent in photodynamic 
therapy 36,117,118. In the former case, most PA imaging approaches to sentinel lymph node 
detection rely on single wavelength imaging, meaning that PA imaging is conducted at 
the wavelength of the absorption peak of methylene blue. As demonstrated in this study, 




method. Hence, using the TTD method for detection of sentinel lymph nodes using 
methylene blue could further improve its efficacy. In the latter case of PDT, the TTD 
method could help to identify and localize the presence of the methylene blue agent in 
the tumor. By first conducting TTD imaging before PDT treatment, peak accumulation of 
the methylene blue in the tumor can be identified before treatment, potentially allowing 
for a superior treatment outcome. As such, future work could involve exploring the use of 
the TTD method in improving both improving the sentinel lymph node detection and PDT 
treatment technologies. In addition, the development of new and novel TTD contrast 
agents can be developed as well. Factors such as the triplet state lifetime, intersystem 
crossing quantum yield, and pump/probe laser wavelengths are all important factors that 
can be explored and considered in the development and discovery of novel TTD agents. 
Chapter 4 demonstrated the use of a repurposed FDA-approved drug called clofazimine 
for prostate cancer detection using PA imaging. The field of drug repurposing is an 
important one as researchers and companies seek to use well-studied drugs with known 
side-effects and apply them in areas outside of their initial intended use. This process can 
potentially save millions of dollars and years of time as much of the work of characterizing 
the drug has already been completed 119. In this study, we used a nanoparticle formulation 
of clofazimine and showed that an intravenous injection of these nanoparticles will result 
in a much larger accumulation in cancerous prostates compared to normal prostates. 
Being a strongly pigmented nanoparticle, clofazimine generates a strong PA signal and 
can be used to distinguish cancerous prostates from normal prostates, at least in an ex 
vivo imaging setting. Future work would include testing this method in vivo. One of the 




imaging depth of the prostate (> 5cm). Currently, methods to bypass this imaging depth 
are being developed. An example of this is the use of a minimally invasive photoacoustic 
needle probe, that can be inserted during needle biopsy, which is a commonly performed 
technique for prostate cancer diagnosis. It was also previously mentioned in Chapter 4 
that clofazimine specifically accumulates in macrophages, making its accumulation in 
tumor associated macrophages a possible tool for extending this drug for use as a 
contrast agent in other cancer models as well. Furthermore, it could also potentially be 
used to study inflammatory responses, or other responses that involve macrophage 
action in the body. 
Chapter 5 demonstrates the use of photoacoustic chemical imaging for quantitative in 
vivo potassium imaging in the tumor microenvironment. In this study, we demonstrate the 
capability of PA imaging, together with a K+ nanosensor, to quantitatively measure the K+ 
concentration in the tumor microenvironment of a mouse tumor. Combined with our 
previous research involving pH and O2, this can potentially allow for tri-chemical imaging 
of the tumor microenvironment. These three chemical parameters (pH, O2, and K+) are 
critical in cancer research due to their corresponding importance in chemo-, radio-, and 
immuno- therapies. These chemicals parameters have been shown to directly affect the 
treatment response of a tumor to these three main cancer treatments. For instance, it is 
well known that the less oxygen in the TME, the less effective are all radio-therapies, as 
all of them are based on singlet O2 and ROS formation 120-122. It has also been shown 
that hypoxia can inhibit the effectiveness of certain chemo-therapeutic drugs including 
vincristine 123,124, melphalan 125, methotrexate 126, and cisplatin 127. Furthermore, O2 has 




are sensitive to environmental oxygen, leading to likely effects on immuno-therapy 
response 128-131. Tumor acidosis, on the other hand, is well known to affect the delivery 
and effectiveness of a large number of chemo-therapy drugs, including paclitaxel, 
mitoxantrone, vincristine, and vinblastine, which all display decreased cellular uptake in 
the acidic TME 132-134. In addition, it has also been shown that acidosis may negatively 
affect both radio-therapy 135,136 and immuno-therapy 137,138. Lastly, K+ has been shown to 
have a suppressive effect on T-cell therapy, as was discussed in Chapter 5 101,139. Future 
work would involve using our photoacoustic chemical imaging technology to study the 
spatial distribution and concentration of these three chemical properties in vivo, and 
subsequently using it to predict and correlate the cancer treatment response of the tumor 
to these chemical parameters. 
In summary, nanoparticle-enabled in vivo photoacoustic molecular imaging of cancer is 
a valuable tool that can empower cancer researchers in not only areas such as cancer 
detection, but also for better understanding the tumor microenvironment and predicting 
the outcome of a cancer treatment. Compared to other nanoparticle-enabled imaging 
technologies that allow for in vivo analysis of tumors, PA imaging has the benefit of the 
vast amounts of research that has gone into the generation and development of optical 
reporters, leading to a large library of available sensors that could be fashioned into 
nanoparticles that can be used to probe for specific molecular information in the body. As 
such, I believe that the work that I have done in this thesis has only scratched the surface 
that is possible in this field, with many more exciting and valuable developments that are 
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